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El sueño de la razón produce monstruos
[The sleep of reason produces monsters]
Francisco de Goya y Lucientes
Los Caprichos, no. 43
1797-1799

One's life has value so long as one attributes value to the life of others, by means of love, friendship,
indignation, compassion.
Simone de Beauvoir
1972

The social structure and the state are continually evolving out of the life-process of definite individuals,
however, of these individuals, not as they may appear in their own or other people’s imagination, but as
they actually are, i.e., as they act, produce materially, and hence as they work under definite material
limits, presuppositions and conditions independent of their will.
Karl Marx
The German Ideology
1845-1847

Men [People] make their own history, but they do not make it just as they please; they do not make it
under circumstances chosen by themselves, but under circumstances directly encountered, given, and
transmitted from the past.
Karl Marx
The 18th Brumaire of Louis Bonaparte
1852
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Abstract
Introduction
The incidence of Hepatitis C virus (HCV) infection has increased in the current opioid epidemic in the
United States; current estimates are that 2-3 million Americans have HCV infection. The ongoing and
increasing HCV epidemic among people who use drugs (PWUD) is occurring in the context of known
HCV prevention and highly efficacious and well-tolerated curative HCV treatment. The development of
direct acting antivirals (DAAs) with cure rates approaching 100% dramatically changed the treatment
landscape. This provides both the potential for improved individual- and population-level treatment
effectiveness, and also the potential for population-level HCV ‘cure as prevention' (CasP) (a key
component of combined prevention) and consideration of the goal of HCV elimination. Medication
assisted treatment (MAT) for opioid use disorder (OUDs) is another important component of combined
HCV prevention. However, the impact of specific MAT program factors on HCV incidence remain
underexplored.
Assessments of the HCV care continuum have identified large gaps in the sequential steps of
HCV prevention and care. Community viral load (CVL) is a measure that has been developed to aide HIV
surveillance and control but has not been developed for HCV surveillance despite many commonalities
between HIV and HCV with respect to transmission, prevention and treatment. Hence, novel measures of
HCV CVL merit study as predictors to identify vulnerable areas and populations, and as predictors of
incidence, to help focus implementation of prevention and treatment and resources.
This dissertation examines outcomes of the HCV care continuum, and factors associated with
linkage to HCV treatment, among PWUD in MAT, proposes novel HCV CVL measures, and examines
HCV incidence, and individual-level factors associated with incidence, and the association of HCV CVL
with area-level HCV incidence in an open cohort of patients receiving MAT.
Methods
Paper 1: A systematic review was conducted to identify conceptual and empirical applications of
CVL constructs to HCV epidemiology. Using the published literature on HCV epidemiology and the HIV
CVL literature, this Paper conceptualized and defined a set of HCV CVL measures constructed to
address specific questions for defined populations.
10

Papers 2 and 3: This is an observational retrospective study of an open cohort of people
receiving MAT in the form of methadone for OUDs at the Mount Sinai Health System (MSHS) opioid
treatment program (OTP) in New York City (NYC), the largest not-for-profit OTP in the US. The study
period is 2013-2016.
Paper 2: Data from patients were used to: 1) identify HCV care continuum outcomes (antibody
and viral load (VL) testing; linkage-to-care; treatment receipt; and cure), 2) operationalize, calculate and
examine geographic variation in engaged-in-care HCV CVLs, 3) calculate both documented and
estimated unmet testing and treatment need, and 4) examine factors associated with linkage-to-HCV-care
in the current era of DAAs and after implementation of qualitative reflex VL testing.
Paper 3: HCV incidence was calculated among those HCV antibody tested >2 times. HCV CVL
was calculated among those with documented, active infection overall and by geographic area of
residence. Incidence rates, incidence rate ratios, and associated factors overall and among specific
subgroups were examined. Kaplan-Meier and Cox proportional hazard models were used to assess timeto-HCV-seroconversion.
Results
Paper 1: The systematic review found that there were no published studies either conceptualizing
or applying CVL measures to HCV identifying this as an important gap in the literature. Five novel HCV
CVL measures were conceptualized, using the literature on HCV epidemiology and the literature applying
CVL to HIV epidemiology. This paper makes a novel and substantive contribution to the literature by
developing CVL measures applicable to HCV epidemiology. This set of HCV CVL measures could be
utilized to address diverse questions relevant to HCV control. One HCV CVL measure (‘engaged-in-care’)
was identified to be calculated and examined further in Papers 2 and 3.
Paper 2: The study included 11,267 patients. Proportions of those HCV antibody tested (52.5% vs. 73.3%), linked to HCV care (15.7% vs 51.8%), and receiving HCV treatment (12.0% vs 44.7%) all
increased significantly in 2015-16 compared with 2013-14 after implementation of on-site qualitative reflex
VL testing. Hispanic ethnicity was associated with lower linkage to HCV care and Manhattan residence
was associated with better linkage to care. The engaged-in-care HCV CVL measure was 6.06 log 10
copies/milliliter (standard deviation: 0.926) and varied significantly by demographic subgroups and
geography. Documented unmet treatment need among those engaged in care decreased significantly
11

(88.0% vs. 55.0%) but remained high; estimated unmet treatment need among the entire study population
was higher still (99.1% vs 86.0%).
Paper 3: Among 8,352 patients tested, HCV prevalence was 48.7%. Among 2,535 patients
seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation (PYO).
Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female gender, drug
injection, and lower MAT retention were significantly associated with higher incidence. Female gender,
drug injection and methadone doses <60mg were independently associated with shorter time-to-HCVseroconversion. HCV CVLs varied significantly by geographic area. For each 1 log 10 increase in HCV
CVL, the HCV incidence rate was expected to be multiplied by about 2.7; although this association was
not statistically significant, these results suggest the importance of further research on this association.
Discussion
This dissertation demonstrates that HCV CVL measures can be constructed and that there are
significant area-level disparities in HCV CVL. My data suggest that measures of HCV CVL may be
valuable in geographically focusing prevention and treatment efforts and that HCV CVL measures merit
further study as potential predictors of HCV incidence.
Analyses identified significant gaps in the HCV care continuum steps of testing, linkage-to-care,
and treatment. Further improvements in rates of complete testing are needed and broader
implementation of HCV reflex testing may be valuable. More effective linkage to care interventions are
needed generally and particularly for those of Hispanic ethnicity. While during the study period the
proportion HCV treated increased significantly, there were still very high rates of unmet treatment need
suggesting that HCV control will require significant expansion of HCV treatment.
The incidence rates observed support recommendations for annual HCV testing of all those in
MAT, not only those who report injecting drugs. Data highlight the need for efforts to improve MAT
retention and ensure adequate dosing. Further studies of and efforts to address identified sex disparities
are needed. Area-level HCV CVL measures may be valuable to geographically focus prevention and
treatment efforts and merit further study as predictors of incidence.
PWUD engaged in MAT continue to be at risk for HCV infection. The large reservoir of PWUD
chronically infected with HCV, and persistently high HCV incidence rates, reinforce the need for vigorous
efforts to improve HCV care continuum outcomes and ensure access to high-quality MAT. Efforts to
12

expand HCV treatment access and engagement are essential to promote HCV CasP and achieve HCV
control among PWUD.
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Chapter 1. Introduction to Dissertation
Thematic area of dissertation
Hepatitis C virus (HCV) has been endemic among people who use drugs (PWUD) for decades.1-6
The current increase in HCV incidence is a consequence and central feature of the recent opioid
epidemic affecting the United States (US).7-10 HCV infection accounts for more than one-third of cases of
hepatocellular carcinoma in the US.11 Deaths due to HCV infection have been increasing in the US since
2009,12 and life expectancy among those with HCV infection is lower than that in the general population. 13
The current HCV epidemic reflects both the burden of untreated infection and the rising incidence of new
HCV infections, and is occurring in the context of known evidence-based HCV primary prevention and of
well-tolerated curative HCV treatment which can be considered as HCV ‘cure as prevention’ (CasP). 14-21
The main link between HCV infection and the opioid epidemic is the transition from initial oral use
to drug injection, and non-sterile injection is the most efficient means of HCV transmission. 22-25 Further,
individuals using opioids may transition back and forth between periods of non-injection and injection use.
The treatment of opioid use disorders (OUDs) through evidence-based medication assisted treatment
(MAT, e.g. methadone or buprenorphine) can reduce injection drug use, therefore reducing HCV risk. 21,2629

Those with OUDs who are not engaged in MAT remain at high risk of acquiring and transmitting HCV. 27
The enactment of the Affordable Care Act provided greater access to treatment for OUDs through

several mechanisms (e.g., regulatory changes in coverage for OUD treatment in insurance plans). 30-32
However, MAT continues to be insufficiently implemented with respect to need. 30-34 For example, in 2015,
it was estimated that over 22 million people >12 years needed MAT but fewer than 9% received
treatment.35 As many as 40 million people with substance misuse (i.e., with risky or harmful substance
use patterns that do not meet substance use disorder criteria) may also go untreated. 36 Disparities in
access to MAT vary considerably by geographic area, race/ethnicity, and gender.37-42 Further, the
increase in the number of for-profit MAT programs, compared to not-for-profit or public MAT programs,
may be contributing to lower quality MAT and less frequent delivery of on-site HCV services. 41,43,44
Past and current epidemiology of HCV
Current surveillance indicates that 114.9 million (95% CI 91.9-148.7) people have been infected
with HCV globally and that in 2015 HCV incidence was 23.7/100,000 people, or 1.75 million new
infections.25,45-48 Among PWUD, global prevalence of HCV ranges from 10% to 97%, with most estimates
being between 50-90% in regions with long-standing injection drug use epidemics (e.g., the US). 49-51
17

Incident HCV infection in the US increased nearly 300% between 2010 and 201552, an increase
which has been temporally linked to the prescription opioid epidemic in longitudinal cohort studies. 9,53,54
This is because the population-level increase in prescription opioid use was temporally followed by
transitions to nonmedical use and to opioid injection.22-24,53,55 Among those aged 18-39, annual HCV
incidence rates increased more than two-fold (0.3 to 0.7/100,000 people) between 2004-2014; rates
increased more than four-fold among females.53 The epidemics of opioid misuse and OUDs, HCV, and
HIV have important degrees of overlap, including that they are occurring in vulnerable areas and among
vulnerable populations, making it valuable to view their co-occurrence as a population-level syndemic. 56-59
Consequences of these area-level vulnerabilities have been highlighted by HIV outbreaks in Indiana and
Wisconsin, and by rural, suburban, and urban outbreaks of opioid misuse, OUDs, and HCV, often in
regions of poverty, high underemployment, and deindustrialization.57,60-66 r
While some published work has examined the prevalence of HCV among non-injecting PWUD,
identifying associated and biologically plausible causative factors, there are sparse data on HCV
incidence among non-injecting PWUD.67 One result of this gap in the evidence base is that while there
are formal recommendations for annual HCV testing for people who inject drugs, the role for HCV testing
among non-injection PWUD is less clear; CDC considers HCV testing among non-injection PWUD to be
of “uncertain need”.67-69
Female sex has been shown to be an important individual-level factor of various HCV-related
outcomes. Females spontaneously clear HCV at a higher rate than males.70-74 Females have faster rates
of progression of liver disease.75-78 Further, disparities in exposure to combined HCV prevention by
gender contribute to differential (lower) protective effects of these interventions for females compared to
males in relation to HCV acquisition.28,79-82 Together, these data suggest that combinations of biologic,
social and structural factors place females at a higher risk for HCV acquisition and sequalae. 26,79 This
dissertation contributes to the literature by directly measuring incidence among men and women engaged
in MAT with both dichotomous and continuous measures of exposure to MAT and engagement in MAT
(Paper 3).
Community viral load (CVL)
Aggregate biologic markers can serve as potent measures for both epidemiology at the
population-level and for evaluation of public health, policy, and program interventions from the clinic level
18

to the county or state level, and among well-defined populations. An example of a widely applied
population-health aggregate measure is herd immunity in the context of vaccine-preventable infections. 83
Another example that relates to HIV control is that of CVL.84-90 CVL is aggregate measure that has been
applied to HIV epidemiology, found to be useful as a measure of geographic disparities, as a program
evaluation measure, and as a predictor of transmission potential.84,85,90
Further, the CDC has recognized that HIV CVL and area-level access to SSPs, ESAP
pharmacies, and MAT can be used to predict area-level vulnerability to HIV and HCV outbreaks. 64,65,91,92
Specifically, combinations of area-level aggregate measures may be useful predictors of opioid, HIV and
HCV syndemic risk and may be modifiable at the public health and policy-level. 10,93-96
The theoretical basis for HCV CVL being a potentially important driver of HCV incidence, based
on analogous experience with HIV and what is known about HCV infectivity, points to the importance of
studies examining this association. As with HIV, the risk of onward HCV transmission from an infected
individual to a susceptible one is directly correlated with the magnitude of HCV viral load of the source
patient.97-100 The association of viral load magnitude with needlestick transmission and analogy with HIV
suggests that the magnitude of HCV viral load in a PWID engaged in distributive sharing will increase the
risk of HCV transmission per event, and that the CVL of PWUDs in a network or an area may be
important predictors of HCV incidence. While differences exist between the relationship between viral
load and HIV and HCV outcomes, respectively, there are abundant similarities (e.g., in modes of
transmission and markers of treatment response and infectivity) suggesting that adapting the CVL
construct to fit HCV, and examining the relationship of HCV CVL to HCV outcomes is an important
scientific line of inquiry and may enhance public health approaches to HCV control.
However, no studies have formally defined or examined HCV CVL constructs. There are no
published guidelines for the construction of HCV CVL measures and there are virtually no published data
of HCV CVL estimates or other group measures or associations with outcomes.101 These constitute
significant gaps in the literature. This dissertation contributes to the literature by developing and
proposing guidelines for the application of the CVL construct to HCV control (Paper 1), by calculating
HCV CVL and examining its geographic variation (Paper 2), and by exploring the relationship between
HCV CVL and HCV incidence (Paper 3).
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Prevention of HCV infection
In New York City (NYC) in the 1990s, approximately 80%-90% of PWID were HCV infected and
50% were HIV infected.102 From the mid-1990s to the mid-2000s, interventions were implemented in NYC
to expand access to sterile syringes through sterile syringe programs (SSPs) and pharmacy sales
permitted by the expanded syringe access program (ESAP), to reduce injection frequency through MAT,
and to ensure access to HIV treatment; these interventions have contributed to significant reductions in
HIV incidence and prevalence.102-105 In NYC, HIV incidence among PWUD has declined to <0.1/100
person-years of observation (PYO), approaching elimination.106
Since HCV is primarily transmitted by non-sterile injection, HCV infection can be prevented by
interventions that reduce or eliminate non-sterile injections, including: a) SSPs and pharmacy syringe
distribution programs; these interventions reduce the proportion of drug injections which are with nonsterile syringes; b) treatment of OUDs with MAT which prevent HCV by reducing the frequency of drug
injection; and c) treatment of HCV infection which reduces the pool of individuals capable of transmitting
the virus.
While HCV prevalence did decline from the 1990s to 2000, due likely to some mix of combined
prevention in the form of SSPs and ESAP pharmacy syringe sales, MAT, and HCV CasP

18,21,80,107-118

and

cohort mortality,119 neither HCV prevalence nor incidence declined to the degree observed for HIV
infection. Serial cross-sectional analyses from 2006-2013 among PWID in NYC found a 67% HCV
prevalence and an estimated HCV incidence among new injectors was 19.5/100 PYO, neither of which
differed significantly from estimates from 2000-2001 in this same patient population. 119,120 Combined HCV
prevention programs remain underfunded and underimplemented, and HCV CasP has not been brought
to public health scale. Meta-analyses, reviews and modeling suggest that combined prevention with MAT,
syringe distribution and HCV CasP will be essential for reducing acquisition of HCV. 18,21,80,107-115
Structural and policy factors in HCV prevention and control
Gaps in MAT implementation, or area-level coverage, constitute a structural barrier that has
implications for components of the syndemic; for example, lower county-level access to buprenorphine is
associated with greater county-level vulnerability to HCV and HIV epidemics. 10,121 A recent study found
that 18 US states lacked any comprehensive HCV prevention strategy for PWUD.52 Specifically, these
states had no laws authorizing a SSP, decriminalizing possession and distribution of syringes and
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needles, or allowing the retail sale of syringes without a prescription. 52 Further, many private and public
health insurers (including Medicaid in many states) have established criteria to limit access to HCV
treatment, often putting in place eligibility restrictions greater than those contained in the FDA approval of
the drugs.122,123 In a recent study, 24 states were found to have “restrictive Medicaid HCV treatment
policies”52 that may serve as barriers to CasP.122,124-131 These data highlight that structural factors are
important in shaping HCV epidemiology, and are barriers to achieving the goal of HCV elimination.
Substance use and substance use treatment
MAT (e.g., methadone) reduces relapse to illicit use and injection and contributes to a wide range
of improved social outcomes.20,111,112,132 Data demonstrate that long-term retention in methadone
treatment is a potent predictor of improved outcomes; further, methadone acts to decrease opioid use
and injection so it also reduces the risk of HIV acquisition.133
As few as one in 10 Americans with SUDs receive any treatment; one-third of those who do not,
cite cost or lack of health insurance coverage as the reason.134 It should be noted that there are nonpharmacologic (i.e. non-MAT) interventions that are still frequently utilized for treatment of OUDs;
however, MAT has consistently been shown to be the most efficacious and effective for the treatment of
OUDs, and only MAT has been shown to have any HCV or HIV preventive efficacy. 135,136 While MAT is
the most efficacious evidence-based treatment for OUDs, only approximately 10% of substance use
treatment facilities in the US offer it.135,137,138
MAT has been shown to decrease morbidity related to opioid use and to decrease the frequency
of injection.21,105,113,114,139 MAT engagement reduces the incidence of HCV.80,81,111,140-145 A 2016 Cochrane
review found current use of MAT, as defined by use within the last six months, reduced the risk of HCV
acquisition by nearly 50%.27 Recent evidence points to MMTP being most effective when treatment is
continuous and when methadone doses are adequate. 142,146 Increased MAT retention has been shown to
be associated with better health outcomes, and factors contributing to lack of retention in MAT include a
combination of individual-level, program-level, and structural-level factors such as adequate doses,
arrests and incarceration events, limited clinic hours, insurance coverage complications, and policies
requiring doses in-clinic.138,146 Additionally, the Cochrane systematic review identified that virtually all
studies examined the impact of MAT using dichotomous measures of exposure. 81 As continuous
measures are more valid and reliable measures of exposure, this represents a gap in the literature. 147
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The HCV care continuum and HCV elimination
The public health and population-level impact of HCV prevention and treatment can be assessed
and monitored using care and prevention continuum models.148-158 Current assessments of the HCV care
continuum have identified large gaps in the sequential steps of HCV care and prevention. 16,148 126,159,160
Only 50% of those living with HCV in the US have been diagnosed with HCV; of those with HCV, only
approximately one-third were referred to care, 7-11% initiated treatment and only 5-6% achieved a
sustained virologic response (SVR).161 Since the treatment of infected individuals decreases the reservoir
of HCV infection, HCV treatment can be viewed as CasP.
Estimates of the proportion of persons progressing through sequential continuum steps are useful
for revealing specific aspects of healthcare and public health systems which, may contribute to
suboptimal individual and public health outcomes through incomplete implementation, efficacy, and
effectiveness. These estimates can inform design and selection of interventions to improve identified
gaps that may have population-level health benefits.162 The World Health Organization has adopted the
care continuum model to track global progression towards the 2030 goal of eliminating HCV as a public
health threat.163
HCV testing is a multi-step process. Approximately 25% of those infected with HCV
spontaneously clear infection, therefore the confirmation of active infection requires additional testing
following a positive HCV antibody test to confirm active viremia, referred to as a viral load test. 71 HCV
antibody testing can be done by finger prick or venipuncture, with results available the same day or in a
few days, respectively, and is generally an inexpensive test. HCV viral load testing can only be performed
by venipuncture (not by finger prick or oral swab testing), has a turn-around time of several days, and is a
more expensive test. In a recent systematic review of the HCV care continuum, I with others identified
heterogeneity in the application of the care continuum construct to HCV with respect to how steps were
defined, measured, and reported, as has similarly been noted with respect to the HIV care
continuum.148,150,164 Fewer than half of the studies reported sites offering on-site viral load testing
following antibody testing. We also found that very few reports addressed more than one step in the HCV
care continuum.148 This is an important gap in the published literature that limits the understanding of the
progression of individuals and populations through the entire HCV care continuum. This dissertation
contributes to the literature by examining both rates of testing, linkage, and treatment (Paper 2).
22

The ‘traditional’ HCV viral load test has been a quantitative HCV viral load test which both detects
and quantifies the density of viremia. The density of viremia in an individual is directly related to the risk of
transmission (perinatally and via needle stick).165 An alternative HCV viral load test which qualitatively
detects the presence of viremia is both 1) less expensive than the quantitative HCV viral load test, and 2)
and can be done as a reflex test, that is, it can be performed on a specimen of blood obtained by
venipuncture if the HCV antibody is found to be positive. HCV testing strategies that increase the receipt
of initial HCV screening tests166 or HCV viral load testing, are directly associated with increases in
proportions of those with chronic infection engaged in HCV treatment and cured.167,168 The impact of
implementing different antibody and viral load testing strategies is examined and discussed in Paper 2.
While HCV testing initiatives can be implemented in sites where PWUD frequent, and where HCV
prevalence and incidence are high, such as SSPs and opioid treatment programs (OTPs), many such
sites cannot either perform venipuncture (and hence cannot do viral load testing to confirm active
infection), or even if they can confirm active infection though viral load testing, may not have the
infrastructure, staffing or funding streams to themselves provide on-site HCV treatment.7,150,154 Therefore,
in many HCV testing settings, those found to be HCV antibody positive (or those found to have active
infection) need to be linked to other clinical settings for further evaluation (e.g., quantitative viral load
testing) and HCV treatment. In a systematic review. Linkage-to-care is therefore a highly variable step in
the care continuum and in the published literature, the step of linkage-to-care occurred variably after HCV
testing, and few published studies examine the linkage step compared to those that have examined the
steps of testing or the outcomes of those engaged in treatment.148 This dissertation contributes to
expanding the evidence base on HCV linkage to care; the proportion linked from MAT to HCV care after
HCV testing is examined and discussed in Paper 2.
The development of all-oral DAAs, with cure rates approaching 100%, dramatically changed the
treatment landscape, creating not only the potential for vastly improved individual and population level
treatment effectiveness, but also creating the potential for population-level CasP. 19,115,169,170 Further, the
availability of these DAAs have led organizations at the US State, Federal, and global levels to discuss
the possibility of HCV elimination.14,169 The WHO established a goal of a 90% reduction in new HCV
infections and a 65% reduction in mortality by 2030.171 Yet, the anticipated beneficial impact of DAAs on
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HCV-related morbidity, mortality, and incidence derives primarily from modeling, and direct evidence for
their impact on mortality rates is scarce.115,172-175 The goal of HCV elimination through expanded
treatment and CasP is thwarted by barriers including medication costs, requirements for medication prior
authorization and insurance based restrictions on treatment, as well as a rise in HCV incidence. 15,163,176,177
In the absence of effective population-level HCV prevention and CasP, the high prevalence of active,
untreated HCV results in a high CVL, which serves as a large HCV reservoir, increasing the probability of
a non-sterile injection episode with HCV contaminated injection equipment. 2,109,178 Thus, accurate
estimates of HCV incidence and of the impact of MAT and HCV CVL on incidence are critical to HCV
control. This dissertation contributes to the literature (Paper 2) by examining the gaps in the HCV care
continuum, from testing to cure, and by providing data to inform interventions to address the identified
gaps. This dissertation further contributes to the literature by calculating estimates of the proportion HCV
treated and unmet treatment need. Further, this dissertation provides data relevant to the HCV care and
prevention continuum by conducting analyses of HCV incidence among those engaged in MAT,
effectively assessing the preventative efficacy of MAT on HCV incidence (Paper 3).
Methods and study design
This dissertation employs several methods including 1) systematic review (Paper 1), 2)
conceptualization and development of CVL measures appropriate for HCV epidemiology (Paper 1), 3) an
observational retrospective open cohort (Papers 2 and 3), 4) use and extension of care continuum
constructs applied to HCV (Paper 2), 5) univariate and multivariate analyses to examine factors
associated with linkage to care (Paper 2), 6) direct measurement and estimation of unmet testing and
treatment need (Paper 2), 7) univariate and multivariate analyses to examine factors associated with HCV
incidence (Paper 3), and 8) Kaplan-Meier and Cox proportional hazards regression to examine factors
associated with time-to-HCV-seroconversion (Paper 3).
In this dissertation, I employed the systematic review method in Paper 1 to assess the gaps in the
literature on studies of the CVL construct as applied to HCV epidemiology. This dissertation then builds
upon prior work and contributes to the evidence base by further addressing some of the gaps identified.
Issues of the specific systems of HCV testing, and of the outcomes of both the distinct testing steps and
the whole sequence of steps of the HCV care continuum are further examined in Paper 2. Further, in
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Paper 3, I contribute to the literature examining the impact of MAT on HCV incidence using both a
dichotomized and a continuous measure of engagement in MAT.
Open observational retrospective cohort
Papers 2 and 3 utilized observational retrospective data from an open cohort of people receiving
OUD treatment with methadone in the Mount Sinai Health System (MSHS) OTP in New York City (NYC),
the largest not-for-profit OTP in the US. The study period is 2013-2016.
Data from the MSHS OTP electronic medical record (EMR) of standard individual-level variables,
key drug use variables, patient zip code of residence, and HCV infection status were examined for the
period 2013-2016. HCV antibody and qualitative and quantitative HCV VL data was also obtained directly
from the commercial laboratories used by the OTP and were merged with the MSHS OTP EMR for
analysis. Population HCV CVL measures were calculated using HCV testing result data from the OTP
and the MSHS EMR. The geographic unit of analysis used in this dissertation is the United Hospital Fund
(UHF) zip codes areas in NYC. The OTP patient population primarily resides in the five boroughs of NYC,
in a wide range of zip codes.
Measuring HCV incidence
There are multiple reasons why measuring HCV incidence among PWUD remains challenging.
Commonly cited is the notion the PWUD may be a “hard to reach” population and that they may poorly
adhere to follow-up clinical and or study visits.77,179 The individual and structural stigmatization of drug use
and of PWUD interfere with PWUD’s ability to both access healthcare regularly and to adhere to study
visits over the time periods required to directly measure incidence.119,120 One result is that many studies
have relied on inferences drawn from alterative study designs such as serial cross-sectional surveys to
estimate, rather directly measure, incidence.119,120,180,181 This dissertation contributes to the literature by
using longitudinal data from repeat HCV testing among patients enrolled in the OTP to directly measure
HCV incidence.
Further, most data on HCV Incidence are on people who inject drugs, and while nonsterile
injection is the most efficient mode of HCV transmission, the inferences based on these data rely on the
assessment that an individual injects drugs. Studies of HCV incidence among people who inject drugs
(whether cross-sectional or longitudinal): 1) vary in recruitment methods, some of which may require self
–identification as a person who injects drugs, 2) rely on self-reported data (sometimes with ‘verification’ by
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physical examination looking for injection sites) with the potential for introduction of various reporting
biases, and 3) vary in their inclusion criteria, assessing either “recent” injection drug use (variously
defined), or “ever” use. Further complicating these study design and analytic considerations is the fact
that individuals may transition between injection and non-injection drug use. Additionally, as noted earlier,
there are data suggesting that non-injection drug use itself may be associated with HCV transmission,
perhaps through sharing of contaminated non-injection drug use equipment.67,182 There are few studies
examining HCV incidence among people who use drugs who do not inject. This dissertation contributes to
the literature by both examining HCV incidence directly through longitudinal data, and by examining HCV
incidence both among those whose main drug use is by injection as well as among those whose main
drug use is not by injection. These data and the specific methods utilized are discussed in Paper 3.
Dissertation specific aims:
Aim 1: Conduct a systematic review of the published literature to identify the conceptual and empirical
applications of CVL measures to HCV epidemiology. Adapt CVL measures constructed for HIV
epidemiology to apply to HCV epidemiology so that they can serve as valuable measures in program
evaluation, public health surveillance, and research on HCV incidence.
Aim 2: Use data from patients enrolled in an OTP in 2013-2016 to 1) identify HCV care continuum
outcomes (antibody and viral load testing; linkage-to-care; treatment receipt; and cure), 2) calculate
and examine geographic variation in engaged-in-care HCV CVLs, 3) calculate both documented and
estimated unmet testing and treatment need, and 4) examine factors associated with linkage-to-HCVcare in the current DAA era and after implementation of qualitative reflex viral load testing.
Aim 3: Calculate HCV prevalence, CVL, and incidence; and to examine the impact of HCV CVL and MAT
program factors (degree of engagement and methadone dose, respectively), on HCV incidence.
Univariate and multivariate Cox proportional hazards regression to assess the relationship between timeto-HCV-seroconversion and individual-level variables including MAT program factors.
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Chapter 2. Paper 1: Community viral load and hepatitis C virus infection: Community viral load
measures to aid public health efforts and program evaluation
Abstract
Introduction
Current estimates are the 2-3 million Americans have hepatitis C virus (HCV) infection. Community viral
load (CVL) measures have been developed for HIV, but not for HCV, to measure both transmission risk
and treatment engagement in programs or areas. This paper conducts a systematic review exploring
gaps in the published literature on CVL constructs that can be applied to HCV and proposes novel CVL
measures adapted to HCV epidemiology.

Methods
A systematic review was conducted. Searches of electronic databases sought to identify published
literature on HCV which discussed or used CVL measures for HCV program evaluation or to characterize
HCV epidemiology. CVL measures developed for HIV were considered, and novel CVL measures were
adapted to apply to HCV.

Results
No reports examining quantitative measures of HCV CVL were identified. Five HCV CVL measures are
proposed. Narrower measures focusing on those engaged-in-care may be useful for program evaluation
and broader measures may be useful for surveillance of HCV treatment rates and transmission risk.

Conclusion
Despite their potential value, CVL constructs have not yet formally been developed and applied to HCV
epidemiology. The proposed CVL measures could serve as valuable HCV program and surveillance
measures; they require further study with real world data.
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Introduction
Hepatitis C virus (HCV) is a preventable blood-borne infection most efficiently spread via direct
parenteral exposure through non-sterile injection practices.1 Current estimates are that 2-3 million
Americans have HCV infection.2-3 Recent surveillance indicates that annual incidence more than doubled
between 2004-2014 and that this increase is directly associated with the current US opioid epidemic, and
transitions from oral opioid misuse to injection drug use.4 These findings highlight the need for informative
measures to enhance policy and public health responses to achieve HCV control.
Community viral load (CVL)—a group-, program-, or area-level aggregate measure of individual
quantitative (e.g., mean or total virion copies/ milliliter) viral loads (VLs)—is a construct that has been
applied to HIV to monitor the progress of prevention and antiretroviral therapy (ART) viral suppression
goals; HIV CVL is central the concept of ‘treatment as prevention’ (TasP). 5 At the individual-level, VL
magnitude is a potent independent predictor of HIV disease progression; 6 it is directly associated with the
probability of vertical,7 sexual,8 and needlestick transmission,9 increasing the risk of transmission
associated with any given exposure event.10 This, along with evidence that HIV VL suppression reduces
individual-level transmission risk, supports the relevance of the magnitude of HIV VL at the area- or
group-level (i.e., CVL) on HIV incidence.11-13
There have been several HIV CVL studies demonstrating associations between decreases in
magnitudes of CVL and decreases in HIV incidence in ecologic analyses, and strong population-level
associations between increased ART coverage, a subsequent decrease in HIV CVL, and a resultant
decrease in HIV incidence.14-17 HIV CVLs have demonstrated relevance as predictors of HIV
incidence,16,18,19 as measures of the population-level impact of prevention and treatment efforts,11,14,15,20
and as measures of area-level disparities in which higher HIV CVLs are associated with higher rates
area-level poverty.11,19,21
Additional work has examined methods of handling missing or unknown VL data (e.g., VLs of
undiagnosed persons) and the importance of population context, further underscoring the potential utility
of CVL measures to reflect both transmission and the implementation of effective care. 6,22,23 In 2016,
Solomon, et al. conducted ecologic analyses to examine three continuous HIV CVL measures as well as
a fourth measure that included both aggregate VL and population prevalence; 6 two of the three
continuous measures and the fourth measure were associated with decreases in HIV incidence, with the
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measure including prevalence having the strongest association. 24 Numerous studies have applied CVL
constructs to HIV epidemiology and have generally found that more inclusive measures, including those
not diagnosed or not in care as well as those in care, (and which therefore may require imputation) are
predictors of HIV incidence and that less inclusive measures (such as “in-care” CVL) require less
estimation and may be useful measures of program effectiveness, but by virtue of being based on in-care
populations, may not be optimal predictors of incidence.6,11-15,17-20,22,25
CVL constructs have not yet been applied to HCV epidemiology or program evaluation. HCV and
HIV have analogous modes of transmission.26 While HCV, like HIV, can be transmitted parenterally,
vertically and sexually, unlike HIV, for HCV non-sterile injection drug use is by far the predominate mode
of transmission.4,27-30 Several lines of data suggest associations between the magnitude of HCV VL and
infectivity.31-33 A systematic review found that in vertical transmission studies, transmission probability was
directly associated with higher levels of viremia.32 The risk of HCV transmission through healthcare
associated needlesticks has also been found to be associated with higher source patient HCV VL; 9 these
direct data and modeling studies have led the Society for Healthcare Epidemiology of America to advise
that HCV infected healthcare workers with HCV VLs greater than or equal to 10,000 copies/mL be
restricted from procedures that might risk exposure.34 Further, these data can be coupled with other data
which have estimated the average volume of blood exposure through non-sterile drug injection practices
for high-and-low dead space syringes as 1 microlitre and <0.001 microlite, respectively. 31 Since viral load
is the concentrate of viral particles per unit volume, the combination of a low volume blood exposure and
a low concentration of virus in that blood (i.e., a low viral load) translates to a low likelihood of exposure to
any viral particles.31
Combined, these data suggest that there may be a gradient of both individual HCV VL and
community HCV VL, with lower viral loads conferring lower transmission risk. This further suggests that as
with HIV both that treatment may similarly constitute HCV TasP, and that measures of HCV CVL may be
useful to HCV control efforts.31,34-36 In the absence of effective area-level or group-level treatment, a high
prevalence of active HCV infection yields a high CVL which then serves as a large HCV reservoir and
increases the probability that a non-sterile injection episode will contribute to onward HCV
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transmission.30,37,38 As HCV treatment durations are short and regimens highly efficacious, group
determinations of HCV VL will generally consist of VL data contributed by those not treated.
This paper conducted a systematic review to catalog the content of, and gaps in, the published
literature on the application of CVL constructs to HCV epidemiology among people who inject drugs
(PWID). This paper then proposes five novel CVL measures specifically constructed for HCV that could
be used in program evaluation, public health surveillance, and studies of HCV incidence.
Methods
The objective of the systematic review was to characterize the published data on applications of
CVL constructs to HCV epidemiology.39,40 (The PROSPERO form can be found in Appendix A) This
systematic review was guided by the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA); a PRISMA flow diagram detailing the net number of potentially eligible reports
retrieved and the evaluation of report eligibility including the net number of reports assessed at each step
and reasons for exclusion was constructed.41
Systematic review methods
Electronic searches were conducted to identify potentially eligible reports published between
01/01/1991-12/31/2017. MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, the
Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed were searched. The search
strings included, but were not limited to, the terms “HCV”, “hepatitis C virus”, “RNA”, and “community viral
load”. (Full search strategy in Appendix B).
Primary data reports of quantitative HCV VL data aggregated at the group-, area-, or programlevel and used to examine HCV transmission, incidence, or program evaluation were eligible for inclusion
in the systematic review. However, in anticipation of a scarcity of published data, we a priori decided to
provide a qualitative assessment of reports that discuss the application of VL constructs to HCV but yet
do not provide quantitative data.
Bridging the HIV literature to construct HCV CVL measures
We sought a systematic review as a method to identify all published data on HCV CVL. We know
that there is a robust and growing literature of HIV CVL measures.5,6,11,12,16,19,22,42,43 Findings from the
systematic review for HCV were primarily desired to assess whether the CVL construct had been
quantitatively applied to HCV, and to inform the construction of HCV CVL measures in this paper.
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However, in the absence of identified quantitative applications of the CVL construct, or other group-level
VL measures, to HCV epidemiology we used the HIV literature to inform the development of CVL
measures applied to HCV. Specifically, we will reconceptualize the CDC proposed HIV CVL measures
and other published HIV CVL measures to HCV epidemiology; the four CDC HIV CVL measures are
presented in Figure 1.5 Each measure reflects considerations at different levels of analysis including
assessing the effectiveness of programs or healthcare systems in achieving viral suppression (i.e., “incare” and “monitored” CVLs) where all (or most) data would be expected to be available, as well as
estimating the reservoir of virus in larger networked populations (e.g., people who use drugs (PWUD)) or
areas, where directly measured quantitative VL data are likely to be incomplete and must therefore be
estimated (i.e., “community” and “population” CVLs).6,11-15,17-20,22,25
Results
Systematic review results
Searches conducted on electronic databases retrieved a total of 727 potentially eligible reports (see
Figure 1). After removing duplicate records, 514 report abstracts were assessed for eligibility; 11 reports
were ascertained as requiring full-text assessment to determine final eligibility. After full-text review, no
report was ultimately eligible as no report presented HCV CVL as an area-level measure nor were VLs
grouped as a mean or median CVL and studied in relation to infectivity and transmission risk.
Qualitative assessment of the HCV VL literature
The reports requiring full-text review (n=11) used mean or median HCV VLs for several purposes
including reports of progression of hepatic injury, of differences in clinical presentation by demographics
or clinical characteristics, of VL testing methods, of relationships with other biomarkers and of outcomes
of clinical trials of investigational anti-viral agents.44,45 45-52 Numerous studies examined the impact of the
magnitude of HCV VL on disease progression, with many demonstrating a direct relationship between
HCV VL and various HCV-induced biologic outcomes, and other studies have not confirmed a direct
relationship.53,54,33,55-57 Factors such as concurrent steatosis, HCV genotype, alcohol use and other

co-morbid conditions have been found to intervene on the pathway between chronic HCV infection
and HCV-induced health outcomes.53,55 In the era of HCV treatment using pegylated interferon, with
or without first generation direct acting antivirals (DAAs) such as boceprevir and telaprevir and even
with the combination sofosbuvir/ribavirin,58 the magnitude of the pre-treatment HCV VL is a
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consistent predictor of HCV treatment response, with higher VLs predicting lower rates of sustained
virologic response (SVR), and longer times to viral clearance.59-61 With the advent of the more potent
currently available DAAs, pre-treatment HCV VL may not be as clinically relevant of a predictor of SVR.
Several reports examined whether HCV VLs varied over time among people with chronic HCV infection
and generally found that, once chronic infection is established, VL does not vary significantly in
magnitude in a sustained manner over time.62-65
Only one report specifically mentioned HCV CVL in the context of enumerating barriers to HCV
elimination; it noted that “combined, these barriers contribute to the persistence of a high community HCV
viral load fueling ongoing transmission” but it did not provide a specific HCV CVL definition or present any
quantitative data.26
The one domain of exception is that several reports examined vertical transmission of HCV. These
transmission studies compared mean or median HCV VL among groups of HCV-infected pregnant
women who did and did not vertically transmit HCV.66-68 A critical distinction between injection-mediated
and vertical transmission is that any uninfected person who injects drugs (PWID) could engage in risk
behavior with any PWID with active HCV infection, giving meaning to aggregates of group VLs for that
individual’s risk, whereas the risk of vertical transmission to any given fetus is not impacted by an
aggregate VLs of a group of pregnant women. Nonetheless, a CVL of HIV infected pregnant women in an
area could potentially be used to predict population-level vertical transmission risk and as a measure of
the effectiveness of implementation of interventions to prevent maternal-to-child transmission.
Reconceptualizing HIV CVL constructs to HCV epidemiology
The systematic review revealed the absence of quantitative CVL constructs applied to HCV
epidemiology as a clear gap in the scientific literature; no definitions or applications of HCV CVL
constructs have been published to date and no report directly developed HCV CVL constructs even from
a conceptual standpoint. Therefore, the published work on HIV CVL constructs and specific
characteristics of HIV epidemiology were used to bridge the gap in the HCV CVL literature by blending
concepts and methods used for HIV CVL measures with the key distinct aspect of HCV epidemiology,
informing the proposed five HCV CVL that follow in this paper.
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While HIV and HCV have many similarities, differences between the two viruses require that the
CVL construct be reconceptualized for HCV epidemiology.27,69-71 (See Table 1 for key differences in the
epidemiology of the two infections) One critical distinction between HIV and HCV is that through both
spontaneous clearance and treatment resulting in SVR, people with HCV infection may become HCV
antibody (anti-HCV) positive yet be VL negative and therefore, not contribute to transmission risk. These
people should effectively be considered uninfected and thus contribute zero HCV VL in the proposed
HCV CVL measures.
Another important consideration in the reconceptualization of HIV CVL measures for HCV epidemiology is
the process of diagnosing infection. For HIV, diagnosis is a one-step process and hence, it is indicated for
HIV CVLs in Figure 1 as consisting of those as either undiagnosed (Box E) or diagnosed (Box D).
However, for HCV infection, different settings employ diverse strategies for identifying active infection
among those anti-HCV positive,72-75 often for operational reasons, either directly performing a quantitative
VL test76 or first performing a qualitative VL test (reliably distinguishing active from resolved infection), 77
followed by a quantitative VL test for those found to have active infection.78 The proposed HCV CVL
constructs are designed to be potentially applicable to all jurisdictions regardless of whether a two- or
three-step HCV testing process is utilized.
Proposed HCV CVL constructs
Figure 3 visually depicts the types of HCV testing data to be used to construct the HCV CVL measures,
including when data need to be estimated; this Figure 3 builds from Figure 1 (where the CDC HIV CVL
measures were visually described). Table 2 then details the five proposed HCV CVL measures including
their respective testing components, imputation considerations, measure applications, and hypothetical
scenarios. For example, given the importance of spontaneous clearance of HCV and the multi-step
testing required for diagnosis of active HCV, the diagnostic steps of sequential antibody testing,
qualitative VL testing, and quantitative VL testing are reflected in Figure 3 as Boxes C, B, and A,
respectively. The five measures reflect increasingly inclusive denominators where more inclusive
denominators include undiagnosed and unidentified individuals who are transiently infected and
spontaneously clear HCV or who achieved SVR after treatment. While the engaged-in-care HCV CVL
relies on only directly measured data, the other CVL measures require assumptions and estimation.

50

Engaged-in care HCV CVL measure: The first and narrowest HCV CVL measure consists of people with
active HCV infection who are engaged-in-care with directly measured HCV CVL data. This measure also
would include those successfully treated who achieved SVRs and hence have undetectable VLs.
Engaged-in-care VL estimates can be directly useful to programs by providing information on the degree
to which the population in-care is virally suppressed. However, by definition this measure does not reflect
VLs among those who are undiagnosed or out of care, or the proportion who move from one region to
another, and hence may not be optimal for predicting incidence.20 For HCV, where treatment durations
are finite and result in viral clearance, HCV VL group determinations will generally consist of VL data
contributed by those untreated (whether in or out of care).
Active infection HCV CVL measure: The second HCV CVL measure includes those with a quantitative
HCV VL result and people without a quantitative VL result but known to be viremic from a positive
qualitative test. This measure does not include those who were never tested for anti-HCV or those who
were anti-HCV tested and were positive but did not have any VL tests. This measure therefore may be
directly useful to programs as a performance measure and to public health authorities in identifying
groups engaged-in-care who remain capable of transmitting the virus and who need treatment.
Diagnosis-based HCV CVL measure: Individuals who have documented anti-HCV positive tests with or
without documented HCV VL tests comprise the third proposed HCV CVL measure. For this measure, in
addition to using directly observed data from those who had quantitative VL tests, values need to be
imputed based on assumptions for both those who had qualitative but not quantitative VL tests and for
those without any documented VL tests. This measure has the potential to be useful both in
characterizing the reservoir of infection among those known to be infected and in reflecting the quality of
care for those known to be infected (i.e., a high diagnosed-based exposure HCV CVL would reflect both a
higher risk of transmission and a lower degree of engagement in care and treatment in this area). Another
useful role of this measure is that it also helps programs to identify the number of those in their program
who need HCV VL testing.
Prevalence-based HCV CVL measure: The fourth proposed measure includes a broader population in
that it includes individuals a) with documented VL determinations (qualitative or quantitative), b) with
documented anti-HCV positive tests but without VL tests, and c) who have never been anti-HCV tested
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and who remain undiagnosed. This measure, “prevalence-based CVL” (Measure 4, Table 2), would
require imputation to estimate the proportion who would be expected to be anti-HCV positive and the
proportion of those with active infection and their respective VL values. This measure could be used to
monitor the potential for HCV transmission.
Population HCV CVL measure: A fifth HCV CVL measure is proposed which is comprised of all of the
groups in the prevalence based CVL as well as those who are HCV negative; measures is analogous to
the measure reflecting prevalence employed for HIV by Solomon, et al.43 Recognizing that there are both
infected and uninfected people in any setting or area, and that the proportion of those dramatically affects
transmission dynamics, this measure could be concretely useful to programs and policymakers as it has
the potential to most fully reflect HCV transmission risk in an area or program.
Discussion
As an index to monitor the potential for viral transmission, reflecting the reservoir of infection
capable of being transmitted within any area or group, CVL incorporates both directly measured and
estimated (e.g., for those undiagnosed or those not in-care) data for the number of infected or viremic
people and the magnitude of VL for each person.5 CVL measures can be applied to entire populations
(using assumptions and imputation to estimate VLs of those undiagnosed or out of care), or to defined
populations such as those in specific programs. CVL can be used for area-level surveillance among
populations linked by transmission relevant factors (e.g., within social-risk networks of PWID) or as a
measure of program-level effectiveness. It is important that CVLs are measured in and applied to clearly
defined populations, be able to reflect variations in CVL over time, and reflect transmission risks and the
degrees of treatment engagement.5
An important consideration when constructing CVL measures for epidemiology and program
evaluation is the need to consider whether the data are serial cross-sectional or longitudinal. Published
studies on HIV CVL have varied in design including both single cross-sectional assessments, 6 serial
cross-sectional designs,16 and longitudinal designs.79 While cross-sectional designs (even serial crosssectional designs) pose limitations on inferences of causality because viral loads can’t be linked back to a
single individual. However, in datasets where risk factor distribution may be more completely
characterized by observation across spatial locations at a single point in time than observations across
time in specific locations, a serial cross-sectional study (albeit ecologic) may perform better in terms of
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risk factor estimation.80 While having the limitation of not being able to account for individual-level
variations in risk, such serial cross-sectional designs may have the advantage of being better able to
detect changes in area-level factors over time (such as, changes in area-level access to sterile syringes
or HCV treatment through changes in policy).80
There are some practical limitations to the use of CVL measures, as mentioned, that relate to
issues of data availability and to the need to estimate missing data, for methods of handling duplicate
data and data for those who may have moved or died. Such methods are particularly important when
combining data across programs and jurisdictions. Specific approaches to doing so are discussed in the
CDC document as well as in subsequent work.6,23,25,43
There are the related issues of who or what constitutes a population and of what constitutes an
appropriately defined area to which the CVL construct is applied, and whether the people therein are truly
interconnected in ways that create the potential for transmission and the issue of the distribution of risk
behaviors in any population so defined.24,81,82 A related potential limitation of place-based inferences is
that people spend different proportions of time in different places doing different things. 83 An individual’s
behavior may be influenced by, or in fact, constrained to different degrees by, the presence or absence of
risk or prevention promoting factors in their area of residence. However, both individuals and areas may
differ with respect to the ease with which services may be accessed from other adjacent or non- adjacent
areas, and the potential impact of disparities in supraindividual factors between an area of residence and
other adjacent areas on individuals.
Further, if those with active infection are not engaging in transmission risk behaviors, then the
magnitude of the VL in that individual does not truly contribute to transmission potential so that there is
the potential introduction of bias in the exposure measurement. This consideration however also applies
to analyses of transmission based on the prevalence of viremic persons (whether for HIV or HCV); such
analyses treat viremia as a dichotomous variable and similarly those who are viremic (regardless of the
magnitude of viremia) only truly contribute to transmission risk if they engage in distributive injection
behaviors. Since risk behaviors change over time, the population of all infected persons constitutes an
important pool from which outbreaks can develop regardless if those with active infection engage in
transmission risk behaviors.84-86 It could inform a general multi-level model of transmission risk including
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both individual risk behaviors and area-level factors including HCV CVL. Nonetheless, as noted, studies
have found that the prevalence of viremic HIV infected persons and the magnitude of HIV CVL are
nonetheless associated with incident HIV infections.11,14,16,42
Conclusion
To date, there have been no CVL constructs conceptualized or applied to HCV epidemiology and
program evaluation. HCV CVL measures may be useful to program and policy decision makers to
evaluate the impact of and need for HCV prevention and treatment services. They may be useful to
monitor area-level trends in HCV epidemiology including degrees of treatment implementation and
engagement and a measure that reflects HCV transmission potential among susceptible populations.
These measures could also be used in quantitative evaluations of any area- or program-level phenomena
including the impact of the implementation of specific interventions (e.g., impact HCV prevention
programs, HCV testing initiatives, scale-up of HCV treatment availability) on HCV incidence and
prevalence. These measures could be used to identify area-level disparities in HCV CVL and to examine
associations between HCV CVL and other relevant structural variables linked to the same geographic
unit. Further study of these proposed HCV CVL measures to HCV epidemiology is warranted.
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Tables and Figures
Table 1. Differences between HIV and hepatitis C virus (HCV) infection that are important in
reconceptualizing CVL constructs
Testing and Diagnosis
HIV
HIV antibody testing is sufficient to make a diagnosis of active infection.
HCV

HCV testing requires at least a two-step process to determine active infection (i.e., a positive
anti-HCV and a detectable HCV VL).
Qualitative HCV VL tests (a dichotomous measure of the presence or absence of detectable
viremia) provide an inexpensive and reliable measure of active HCV infection.
If qualitative HCV VL tests are used to screen positive anti-HCV tests (a decision often made for
cost-saving) then it becomes a three-step testing process to determine quantitative HCV VL.
There is significant heterogeneity among HCV programs as to whether a positive HCV antibody
test prompts referral elsewhere for VL testing or whether antibody testing prompts on-site VL
testing with subsequent referral only of those with detectable VLs.87
Variations in this two- or three-step testing process create an important category of those
incompletely diagnosed, i.e., those found to be antibody positive but who are not VL tested.

Natural History and Viremia
HIV
While acute HIV infection is associated generally with an initial very high HIV VL followed by a
generally lower HIV VL, it is virtually never followed by spontaneous viral clearance and all
those HIV infected and untreated remain viremic forever.
HCV

Approximately 25% of those who are infected with HCV will spontaneously clear the virus
(without intervention).88
Those who have spontaneously cleared HCV infection do not contribute to transmission risk but
do remain susceptible to re-infection with HCV.

Anti-Viral Treatment
HIV
HIV treatment does not result in cure.
Consequently, any HIV infected person requires lifelong care, having distinct measures for
those engaged in care (the in-care or monitored VL measures) reflects an important population
because of the ongoing need for treatment and viral suppression.
HCV

HCV treatment is a transient state (typically 8-12 weeks) after which most people are done with
treatment and are cured, retaining a positive anti-HCV but no detectable VL.
Given that treatment durations are finite, an “in-care VL” and “monitored VL” may not be
particularly relevant metrics for HCV.
Those treated and cured do not contribute to CVL measures but do remain susceptible (a
scenario similar to those who spontaneously clear HCV infection).
As HCV treatment is highly efficacious and treatment durations are short, group HCV CVL
measures will consist of VL data contributed by those not treated (whether in or out of care).
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Table 2. Five proposed hepatitis C virus (HCV) community viral load (CVL) constructs
Engaged in care
• Includes those with documented quantitative HCV VL test results.
CVL
•
Measure 1
• This is a directly measured construct which is constructed by aggregating
quantitative VL tests.
No imputation or estimation of data are required for this measure.
•

Hypothetical
scenario
Active infection
CVL
Measure 2

The population of 10,000 in a drug treatment program where 60% of them have
active HCV and 75% had quantitative HCV VLs available, the total number of
individuals contributing to the HCV CVL would be 4,500 people
• Includes those with active HCV infection by documentation of qualitative
VL tests, with or without quantitative VL tests.
•
•
•

Hypothetical
scenario
Diagnosis-based
CVL
Measure 3

The measure provides programs with a minimum estimate of the number
with active HCV infection and the magnitude of CVL; it characterizes the
effectiveness of the program’s prevention and treatment efforts and
identifies the extent of the need for treatment and the specific individuals
who need treatment.

Imputation of VLs is required for those without quantitative VL tests.
This measure provides programs with a fuller estimate of those who have
active infection and who need fuller evaluation and treatment.

The population of 10,000 in a drug treatment program where 60% of them have
active HCV and 80% had qualitative HCV VL testing, but may or may not have
had quantitative VL testing, the total number of individuals contributing to the HCV
CVL would be 4,800 people
Includes those with documented exposure to HCV by virtue of having been found
to have a positive anti-HCV test; these people may or may not have had VL
testing (qualitative or quantitative, or both).
Imputation will be needed to estimate the proportion of those with positive antiHCV tests who in fact have active infection. For those who did not have any VL
tests, imputation will be needed to estimate the proportion who are viremic; this
proportion can be reliably imputed informed by well-established data that 25% of
those exposed will have spontaneously cleared the virus and thus will not have
active infection and will not contribute to CVL. Further, quantitative VLs will need
to be imputed for those who only had qualitative VL tests as well as for the
proportion of those who did not have any VL tests but were anti-HCV positive and
are projected to have active infection (i.e, to not have spontaneously cleared).

Hypothetical
scenario
Prevalence-based
CVL
Measure 4

The population of 10,000 in a drug treatment program where 80% of them have
been exposed to HCV and 95% had antibody HCV testing, but may or may not
have had quantitative VL testing, the total number of individuals contributing to the
HCV CVL would be 7,600 people
Includes those with or without quantitative VLs, those with qualitative positive VLs
but not quantitative test results, those with anti-HCV positive tests but without any
VL tests; and for those without any documented anti-HCV testing.
Imputation will need to be conducted, as described above for the diagnosis-based
CVL, with the addition of imputation for the proportion who were not anti-HCV
tested (i.e., undiagnosed cases) but are truly HCV infected.
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In settings where a large proportion have received antibody testing, there should
not be a substantial difference between the prevalence- and diagnosis-based HCV
CVL measures.
This measure is analogous to the “population HIV VL” measure proposed in the
CDC HIV CVL family of measures.5
Like the population VL, this measure could be valuable to public health authorities
to monitor the population risk of transmission and the state of treatment
engagement in this area. Further, it could be useful to public health authorities to
construct CVLs for different areas and to identify disparities in CVL that would
benefit from public health intervention.
Hypothetical
scenario
Population CVL
Measure 5

Hypothetical
scenario

The population of 10,000 in a drug treatment program where 80% of them have
been exposed to HCV, the total number of individuals contributing to the HCV CVL
would be 8,000 people
Includes those with or without quantitative VLs, those with qualitative positive VLs
but not quantitative test results, those with anti-HCV positive tests but without any
VL tests; and for those without any documented anti-HCV testing as well as those
who are HCV negative in the population. This uninfected group consisting of the
following known and measurable groups: 1a) those testing anti-HCV negative, 1b)
those testing anti-HCV positive and VL negative; and two unmeasured groups
which require imputation: 2a) those anti-HCV positive and not VL tested who are
truly VL negative, and 2b) those not tested for antibody but truly anti-HCV
negative.
•
• Imputation will be needed as described above for the prevalence-based
CVL; in addition, imputation will be need for groups 2a and 2b as above.
•
Where data can be reliably estimated or measured directly, the population VL may
be the best measure for assessing transmission and could be used by health
departments, policy makers, or programs to plan of the allocation of resources to
address and prevent infections and to predict trends in incidence at the
population-level.
The population of 400,000 in an area where 10% have active HCV, the total
number of individuals contributing to the HCV CVL would be 400,000 people
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Chapter 3. Paper 2: Hepatitis C virus (HCV) care continuum outcomes and engaged-in-care HCV
community viral loads among patients in an opioid treatment program
Abstract

Introduction
Hepatitis C virus (HCV) remains endemic among people who use drugs (PWUD). Measures of
HCV community viral load (CVL) and HCV care continuum outcomes may be valuable for
ascertaining unmet treatment need, and for HCV surveillance and control.
Methods
Data from patients in an opioid treatment program during 2013-2016 were used to: 1) identify
proportions antibody and viral load (VL) tested; linked-to-care; treated; in 2013-2014 and 20152016, pre- and post- the implementation of qualitative reflex VL testing; 2) calculate engaged-incare HCV CVL, and documented and estimated unmet treatment need; and 3) examine factors
associated with linkage-to-HCV-care.
Results
Among 11,267 patients, proportions HCV antibody tested (52.5% in 2013-14 vs. 73.3% in 201516), linked-to-HCV care (15.7% vs 51.8%), and treated (12.0% vs 44.7%) all increased
significantly. Hispanic ethnicity was associated with less, and Manhattan residence was
associated with improved, linkage-to-care. Engaged-in-care HCV CVL was 4,351,079
copies/mL (SD= 7,149,888); they varied by subgroups and geography. Documented and
estimated unmet treatment need decreased but remained high.
Conclusion
After qualitative reflex VL testing was implemented, care continuum outcomes improved but
gaps remained. High rates of unmet treatment need suggest that control of the HCV epidemic
among PWUD will require expansion of HCV treatment coverage.
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Introduction

Highly efficacious and well-tolerated direct acting antivirals (DAAs) can cure hepatitis C
virus (HCV) infection.[1] However, an estimated 28-75% of chronically infected people are not
aware of their HCV infection.[2] It is estimated that in New York City (NYC), fewer than 30% of
those with chronic HCV infection were treated in 2015-2017;[2] the national estimate is 17%,[3]
reflecting significant gaps in the HCV care continuum.[4]
People who use drugs (PWUD) can be successfully treated and cured of HCV infection
with both individual-level benefits and as serving as cure as prevention (CasP).[1, 5] With HCV
incidence rates of 10-40/100 person-years and chronic infection prevalence ranging from 4385%, HCV contributes significantly to preventable morbidity and mortality among PWUD.[6-8]
Endemic HCV among PWUD is a function of both the incomplete effectiveness and
implementation of medications for opioid use disorder (MOUD) and of syringe service programs
(SSPs), and of low levels of screening, diagnosis and treatment of HCV among PWUD.[9-18]
Community viral load (CVL)—a group-, program-, or area-level aggregate measure of
individual quantitative viral loads (VLs)—is a construct that has been applied to HIV
epidemiology to assess the program and population-level impact of prevention and treatment
interventions.[19-24] Studies of HIV CVL have examined a range of CVL measures of greater or
lesser inclusiveness; these measures either rely entirely on directly measured data among
those engaged-in-care,[19, 22] and which may therefore be useful program or intervention
evaluation measures and measures for routine surveillance, or be broader measures which
endeavor to reflect infection prevalence, transmission potential and VL burdens among those
not yet diagnosed or linked-to-care, and which may have more generalizable population-level
utility.[23, 24]
The magnitude of HCV VL increases the risk of onward transmission,[25-27] and
quantitative HCV VLs are a standard component of treatment evaluation.[20, 25] HCV
quantitative VL tests however, are consistently more expensive than qualitative HCV VL tests.
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.[28, 29] The common screening strategy of performing HCV antibody testing only, and referring
those with positive tests to other settings for VL testing, has contributed to gaps in the HCV care
continuum. Some settings have addressed this by incorporating HCV VL reflex testing where
qualitative VLs, which provide a dichotomous measure validly detecting active viremia and
chronic infection, are reflexively performed on antibody positive specimens.[30-35]
Despite similarities in modes of transmission and prevention between HIV and HCV,
CVL measures have scarcely been applied to HCV.[36] Analogous to HIV epidemiology, a
family of HCV CVL measures could be constructed ranging from broad measures which would
require imputation for missing VL values for those undiagnosed, to measures that rely entirely
on directly measured data, such as an engaged-in-care HCV CVL. An engaged-in-care CVL
measure is a practical measure for a program or jurisdiction to calculate, since it can be
calculated without additional data manipulation.[19] The Houston Health Department recently
calculated an engaged-in-care HCV CVL, and identified geographic CVL variations which could
geographically focus future HCV prevention efforts.[36]
Opioid treatment programs (OTPs) are important settings for engaging PWUD in the
HCV care continuum and linking them to HCV care.[3, 19, 37-40] The objectives of this paper
are to 1) utilize data from patients enrolled in an OTP in NYC to examine HCV care continuum
outcomes for two time periods (2013-2014 and 2015-2016, respectively) which reflect periods of
different program testing strategies (antibody testing then off-site referral, or antibody then reflex
qualitative VL testing and off-site referral) and 2) examine factors associated with linkage to
HCV care.[22] We also 3) use directly measured HCV VL data to construct engaged-in-care
HCV CVLs and to examine variations among demographics subgroups of OTP patients and
geographic variation based on OTP patient area of residence.

69

Methods

The OTP, part of a large not-for-profit healthcare system in NYC, provides MOUD for
approximately 6,000 patients at any given time in separate clinics distributed throughout
Manhattan and Brooklyn.
Dataset
Data from patients seen in the OTP from 01/01/2013-12/31/2016 were collected from the
electronic medical record (EMR) and included HCV antibody, qualitative and quantitative HCV
VL tests, HCV care, HCV treatment, and demographic information.
Data were examined as two sequential cross-sectional time periods for patients in the
OTP during 2013-2014 (off-site referral of those with a positive HCV antibody test for
quantitative HCV VL testing) and during 2015-2016 (reflex qualitative HCV VL testing for those
with positive HCV antibody tests and subsequent off-site referral for quantitative HCV VL testing
of those with reactive qualitative HCV VL tests).
HCV Testing
OTP patients were routinely offered opt-out HCV antibody testing at program entry and
annual evaluations (patients were tested unless they declined testing or were already known to
be antibody positive). Prior to 2015, HCV testing for OTP patients was a two-step process: 1)
on-site HCV antibody testing, and 2) passive referral of those with positive HCV antibody tests
from the OTP to other affiliated clinical sites for clinical evaluation and diagnostic tests including
HCV quantitative VL tests. Beginning in January 2015, the HCV testing strategy was changed to
a three-step process: 1) on-site HCV antibody testing with 2) reflex qualitative HCV VL testing
and 3) passive referral for off-site HCV VL quantitative testing and HCV care. Throughout the
four-year study period (2013-2016), all HCV antibody tests were done on-site and quantitative
HCV VLs were performed at non-OTP HCV care sites.
HCV Care Continuum
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We compared the following HCV care continuum outcomes for 2013-2014 and 20152016: 1) HCV antibody tested and number positive, 2) HCV qualitative and/or quantitative HCV
VL tested and number with documented viremia, 3) HCV linkage-to-care, defined as having
attended a clinical evaluation for diagnostic tests including having had a quantitative HCV VL
test, 4) HCV treatment, defined as evidence of HCV treatment in the EMR, and 5) achieving
sustained virologic response (SVR), defined as having both an undetectable HCV VL at some
time after the completion of treatment and a clinician note stating that the patient achieved SVR.
These data were used to calculate documented unmet treatment need (defined as the
proportion with documented viremia not known to have been treated) and estimated unmet
treatment need (defined as the proportion estimated to have active infection in the whole study
population assuming a 25% rate of spontaneous clearance).[41, 42]
HCV CVL Calculations
The engaged-in-care CVL includes only directly measured data from patients in the OTP
who have documented antibody, qualitative and quantitative HCV testing data, representing
those successfully linked-to-HCV-care from the OTP. We calculated the HCV CVL by using the
most recent HCV VL test in 2015-2016; that is, patients who were linked-to-care following a
positive HCV qualitative VL test. Engaged-in-care HCV CVLs were constructed by adding each
individual’s most recent HCV VL test and dividing by the number of persons contributing to each
measure, and are reported as means with standard deviations (SDs). We report the overall
engaged-in-care HCV CVL; and then for demographic and geographic (UHF area) subpopulations in 2015-2016.
Patients were coded by their zip code of residence in 2013 or at OTP entry if that
occurred after 2013. The 179 zip codes in NYC were converted to United Hospital Fund (UHF)
zip code areas[43] for analysis. Some UHF areas had <10 residents; therefore, we collapsed
the 34 UHF zip code areas into 30 areas for analyses.
Linkage from OTP to HCV Care and Treatment Settings
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We examined univariate and multivariate factors associated with receipt of quantitative
VL testing (i.e., successful linkage-to-care) among those in 2015-2016 who were found to have
active HCV infection by reflex qualitative VL testing.
Age was examined as a categorical variable. Race/ethnicity was examined as a
categorical variable: non-Hispanic White, non-Hispanic Black, Hispanic, and other
race/ethnicity. Both NYC borough and UHF zip code area of patient residence were examined
as geographic units.
Data Analysis
Categorical variables are presented as frequencies and proportions; continuous
variables are presented as medians with interquartile ranges (IQRs). Comparisons among
overall OTP program care continuum outcomes between 2013-2014 and 2015-2016 were made
using Chi-square tests.
First, we examined differences in demographic and geographic characteristics of
patients who were linked-to-care in 2015-2016. We used binary logistic regression for univariate
analyses and present unadjusted odds ratios (ORs) with 95% confidence intervals (CI) and pvalues. The multivariate logistic regression model was constructed using variables that were
significant in univariate analysis along with those previously shown in the literature to be
associated with the outcome (such as gender)[44] and report adjusted-ORs (AORs) with 95%
CIs.
Second, we examined differences in the engaged-in-care HCV CVL among
demographic and geographic subgroups in 2015-2016. HCV CVLs were transformed to the
log10 scale for analyses[19] and are presented untransformed in the tables and text. Engagedin-care HCV CVLs among demographic subgroups were compared and UHF zip code areas
were examined using linear regression. Data were analyzed using R and SPSS (version
25.0).[45, 46] Significance was determined at the p < 0.05 level. This research received
Institutional Board Approval at respective institutions.
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Results

Study Population
There were a total of 11,267 unique OTP patients during the four year study period. This
includes 2,743 patients seen in the OTP only in 2013-2014; 2,631 patients seen only in 20152016; and 6,296 patients seen at the OTP from 2013-2016. The total number of patients
contributing to 2013-2014 and 2015-2016 data was 9,039 and 8,927, respectively. The
distribution of the patient characteristics did not vary significantly from 2013-2014 to 2015-2016.
(Table 1)
HCV Testing at the OTP
In 2013-2014, 4,744 of the 9,039 (52.6%) patients were HCV antibody tested. (Table 2;
Figure 1) Patients who did and did not receive antibody testing did not differ significantly with
respect to the factors Table 1. (data not shown) There were 15.7% (270/1,720) linked-to-care
among those found to be HCV antibody positive. In 2015-2016, 6,545 of the 8,927 (73.3%)
patients were HCV antibody tested, of whom 3,313 (50.6%) were antibody positive; 90.2%
(2,987/3,313) of those found to be HCV antibody positive had HCV qualitative VL tests
performed; of these, 61.2% (1,828/2,987) were found to be viremic and 946 were linked-to-care
(51.8%); of these, 939 (99.3%) were viremic. (Table 2; Figure 1)
There was a significant increase in the proportion who had HCV antibody testing
performed in 2015-2016 compared to 2013-2014 (73.3% vs. 52.5%, p <0.001). Similarly, there
was a significant increase in the proportion linked to HCV care within this health system (15.7%
vs. 51.8%, p <0.001), albeit at different stages in the testing process.
Linkage to HCV Care Among Those with Active HCV Infection, 2015-2016
In univariate analysis, those of Hispanic ethnicity were significantly less likely to be
linked-to-care (OR=0.71; p-value<0.01). Those living in the Bronx (OR=0.58), Queens
(OR=0.66), and Brooklyn (OR=0.70) were significantly less likely to be linked-to-care compared
to those living in Manhattan (all p-values<0.03). (Table 3)
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As county of residence and UHF zip code of residence represent comparable constructs,
and were highly correlated (p<0.01), borough of residence was retained for multivariate
analysis. The multivariate model also included sex, race/ethnicity, and age. Hispanic ethnicity
remained significant in the model; those who were Hispanic were less likely to be linked-to-care
than non-Hispanic whites (AOR=0.68; p-value<0.01). Those residing in the Manhattan were
more likely to be linked-to-care than those residing in other boroughs (AOR=1.7; p-value<0.01).
(Table 3)
HCV Treatment
In 2013-2014, 88.7% (234/270) of those having quantitative VL tests were found to be
viremic; of these, 12% (28/234) received DAA HCV treatment within this health system. (Table
2; Figure 1) Of those treated, 98.6% (25/28) achieved an SVR. In 2015-2016, 99.2% (939/946)
of those having quantitative VL testing had confirmed viremia; of these, 44.7% (420/939)
received HCV treatment of whom 98.6% (414/420) achieved SVR. (Table 2; Figure 1) The
proportion of those found to be viremic and engaged in HCV care who received HCV treatment
increased significantly (12% vs. 44.7%, p<0.001. (Table 2)
Engaged-in-Care HCV CVL Measures
The overall engaged-in-care HCV CVL was 4,351,079 copies/mL (SD=7,149,888;
n=1,071), and did not decrease significantly from 2013-2014 to 2015-2016 (p=0.13). Table 4
depicts HCV engaged-in-care CVL measures for demographic and geographic subgroups at the
OTP for 2015-2016. In regression analyses, there were significant variations in mean engagedin-care CVL by sex, race/ethnicity, age, and employment status. (Table 4) Engaged-in-care
HCV CVLs varied significantly among the 30 UHF zip code areas (p=0.02; Table 4) with a range
of 74-77,656,774 copies/mL (lower and upper bounds of the SDs for the lowest and highest
UHF area CVLs were 123,945-20,844,208 copies/mL, respectively).
Overall HCV Care Continuum Outcomes
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There were a total of 1,173 individuals with documented HCV infection in 2013-2016;
448 (38%) were linked-to-care and initiated HCV treatment, of whom 439 achieved SVR
(98.0%). The proportion receiving HCV antibody testing was significantly higher in 2015-2016
than in 2013-2014 (73.3% vs. 52.5%, p<0.001). If the HCV antibody prevalence identified in
2015-2016 (50.6%) is assumed to reflect the true OTP cohort prevalence, an additional 2,173
(i.e., 50.6% of the 4,295 not antibody tested) and 1,205 (i.e., 50.6% of the 2,382 not antibody
tested) patients in 2013-2014 and 2015-2016, respectively, may have been HCV antibody
positive but not identified.
With the implementation of reflex testing in 2015-2016 the proportion of those HCV
antibody positive whose viremic status was ascertained increased significantly from 5% to
63.1% (p<0.001).
In 2013-2014, 84.3% (1,450/1,720) of those found to be HCV antibody positive did not
have VL testing. Assuming a 25% spontaneous clearance rate, 1,088 would be expected to
have active viremia. If in addition one assumes that 2,173 of those not antibody tested may
have been antibody positive, assuming a 25% clearance rate, there would be an additional
1,630 who were likely viremic, which, when combined with the 234 with documented viremia,
suggests a total 2,952 viremic patients (32.7% of 9,039).
In 2015-2016, 9.8% (326/3,313 HCV antibody positive) did not have VL testing.
Assuming a 25% spontaneous clearance rate, 245 would have had active viremia. Assuming
that 1,205 of those not antibody tested were antibody positive, with a 25% clearance rate, there
would be an additional 904 who were likely viremic, which when combined with the 939 with
documented viremia suggests a total of 1,843 viremic patients (20.6% of 8,927).
The documented unmet treatment need was 88.0% (206/234) and 55.3% (519/939) in
2013-2014 and 2015-2016, respectively. Again assuming 25% spontaneous clearance and a
true population prevalence of 50.6%, the estimated unmet treatment need was 99.1%
(2,924/2,952) and 86.0% (2,551/2,971) in 2013-2014 and 2015-2016, respectively. Both the
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documented and the estimated unmet treatment need decreased significantly from 2013-2014
to 2015-2016 (p<0.001) but remained high.
Discussion

In this study of PWUD in an OTP, while HCV care continuum outcomes were
significantly improved in 2015-2016 when reflex qualitative VL testing was employed; however,
large numbers of patients remained undiagnosed or incompletely evaluated and unmet
treatment need and engaged-in-care CVLs remained high. While combined prevention
programs have resulted in dramatic declines in HIV infection among PWUD, the effect of
combined prevention on the incidence and prevalence of HCV infection has been more
modest.[8, 10] While the observed HCV antibody prevalence in this cohort was only 30.6% in
2013-2014, and was 50.6% in 2015-2016, it is not likely that this represents a real increase in
prevalence but rather that the opt-out antibody testing conducted in 2013-2014 led to
undertesting of those known or suspected to be previously positive; it is plausible that the
combination of the availability of DAA treatment and reflex qualitative VL testing either
motivated patients to more readily accept testing or that staff more effectively encouraged
testing in 2015-2016. Prior to the implementation of combined prevention (2000-2001), HCV
infection prevalence in this OTP was approximately 90%,[8, 47] while in recent cross-sectional
surveys reflecting either 2006-2013, 2011-2015, 2007-2017 it has been 60-69%.[20, 47, 48] The
inference that the true OTP cohort prevalence in 2013-2014 was 50.6% may therefore be a
conservative estimate.
There was also a significant increase in the proportion linked-to-care in 2015-2016. This
too may have been due to improved program linkage efforts, or of identifying active infection
through reflex qualitative VL testing, or to the potentially motivating impact of DAA availability.
The two different testing strategies reflected in 2013-2014 and 2015-2016 represent two of the
testing strategies that are commonly employed in OTPs and HCV testing sites nationally.[30,
31] Care continuum analyses included some participants who appear in both time periods and
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hence are not independent samples. However, their inclusion reflects recommendations for
annual testing and reflects program-level outcomes in each time period. Hence, while not a
controlled study, and while DAA availability may have been motivating, the data are consistent
with the inference that implementation of reflex VL testing may contribute both to greater testing
rates and improved to linkage-to-care.
Among those found to have active HCV infection by reflex testing in 2015-2016,
Hispanics were less likely than non-Hispanic Whites to be successfully linked-to-care. Further,
there was significant geographic variation in the proportion successfully linked-to-care
suggesting that geographically focused efforts are needed to enhance access and linkage to
treatment. There was also a significant increase in treatment rates among those linked-to-care.
While reasons for this are not certain, it is likely that both the wider availability of oral DAA
therapy and wider acceptance that HCV treatment can be effective among PWUD contributed to
these increases.[1, 5, 44]
A range of CVL measures have been developed and applied to the surveillance and
study of HIV epidemiology; these include measures relying only on directly measured data that
may be practically employed by diverse programs and jurisdictions, as well as broader
measures that attempt to account for undiagnosed people and for area-level prevalence that
may require both more complete area-level surveillance, statistical methods such as
adjustments for duplicate case reporting and multiple imputation.[20-24, 49, 50] The application
of the CVL construct to HCV epidemiology is novel; to our knowledge there is only one
publication, by Arnold, et al. from the Houston Department of Health, reporting an engaged-incare HCV CVL derived from directly measured data.[36] The engaged-in-care CVL provides a
practical measure for programs and jurisdictions.[19, 22, 36] The engaged-in-care HCV CVLs in
our study of OTP patients varied significantly among demographic subgroups and by
geographic area; Arnold, et al. also identified geographic variation in their HCV CVL study.[36]
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Further research of various HCV CVL measures and of their geographic variations and potential
relationship to incidence is warranted.[23, 24, 36]
While rates of HCV testing, linkage-to-care, and HCV treatment all increased
significantly from 2013-2014 to 2015-2016, engaged-in-care HCV CVLs did not decrease over
time. This is likely due to the fact that despite significant increases in testing, linkage and
treatment, there still remained a very high unmet treatment need. While those treated in 20132014 contributed a VL of zero to the engaged-in-care CVL for 2015-2016, we found there were
too few patients treated to have a significant impact on HCV CVL. These findings are consistent
with the observation that current combined HCV prevention strategies, which in NYC include
ready availability of sterile syringes through SSPs and pharmacies, has not included a sufficient
expansion of HCV treatment.[3, 4] These data strongly suggest that further improvements in
testing and linkage-to-care are needed to address the large unmet treatment need, both among
those with documented chronic infection, and among those who remain incompletely diagnosed,
in order to control the HCV epidemic among PWUD.
Limitations
Several important limitations should be noted. As the data were extracted from EMRs,
detailed individual-level HCV risk data, such as frequencies of non-sterile injection or use of
SSPs, and HIV status, were not available. Further, as data were of OTP patients, the HCV
prevalence identified is neither a general population prevalence nor one of all PWUD; the age of
the OTP cohort might contribute to overestimation, and the opt-out testing strategy may
contribute to underestimation, of HCV prevalence among PWUD generally. Nonetheless, the
increases in the proportion antibody tested, the proportion whose virologic status was fully
ascertained, and the proportion linked-to-care, did significantly increase in 2015-2016. While
treatment response rates were excellent, not all post-treatment VL assessments were
performed at > 12 weeks post-treatment; nonetheless 98.6% of PWUD treated were deemed by
their treating clinicians to have been cured.
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Additionally, engaged-in-care HCV CVLs only reflect data for those successfully linkedto-care, and in settings such as this, with high proportions not fully tested or linked-to-care,
underestimate a true population-level CVL. While the numbers and proportions not antibody or
VL tested rely on directly measured data, the estimates of undiagnosed, HCV-infected patients
and of unmet treatment need relied on assumptions of prevalence and of spontaneous
clearance rate. Further, data examined are from patients in a single large OTP receiving care in
one large healthcare system, and are not from a population-based representative cohort,
potentially limiting generalizability and potentially contributing to outcome misclassification as
some patients may have received care elsewhere.
Conclusion
In 2015-2016, in which reflex qualitative VL testing was implemented and DAAs were
available, care continuum outcomes improved significantly; broader implementation of reflex
testing may be valuable. However, very relevant care continuum gaps remained. Both rates of
linkage-to-care and of engaged-in-care HCV CVLs among the OTP patients studied, varied
significantly geographically suggesting that geographically focused efforts to improve linkage-tocare and expand treatment coverage of OTP patients are needed. While the proportion treated
increased significantly, there were still very high rates of unmet treatment need. These data
suggest that control of the HCV epidemic among PWUD will require both the implementation of
strategies for more complete testing and linkage-to-care of OTP patients, and will require a
significant expansion of HCV treatment.
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Table 1. Individual characteristics of OTP patients for the study period, 2013-2016
2013-2014 time period 1, N = 9,039

2015-2016 time period 2, N = 8,927

N

n / N for total time period

%

N

n / N for total time
period

%

Patients in time period 1 only (2013-2014)

2,743

2,743 / 9,039

30.3%

n/a

n/a

n/a

Patients in time period 2 only (2015-2016)

n/a

n/a

n/a

2,631

2,631 / 8,927

29.5%

Patients in both time periods

6,296

6,296 / 9,039

69.7%

6,296

6,296 / 8,927

70.5%

Total patients contributing to time period

9,039

9,039 / 9,039

100.0%

8,927

8,927 / 8,927

100.0%

2,449

2,449/9,039

27.1%

2,451

2,451/9,039

27.1%

6,590

6,590/9,039

72.9%

6,476

6,476/9,039

71.6%

1,988

1,988/9,039

22.0%

1,927

1,927/8,927

14.8%

Hispanic

4,012

4,012/9,039

44.4%

3,892

3,892/8,927

43.6%

White, non-Hispanic

2,419

2,419/9,039

26.8%

2,537

2,537/8,927

28.4%

Other race/ethnicity

9,014

581/9,039

6.4%

571

571/8,927

6.2%

18-24

280

280/9,039

3.1%

432

432/8,927

4.8%

25-34

1,254

1,254/9,039

13.9%

1,457

1,457/8,927

16.3%

Time period

Sex

Female
Male
Race/ethnicity

Black, non-Hispanic

Age (in years)a
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35-44

1,768

1,768/9,039

19.6%

1,866

1,866/8,927

20.9%

45-54

3,030

3,030/9,039

33.5%

2,904

2,904/8,927

32.5%

55-64

2,264

2,264/9,039

25.0%

1,956

1,956/8,927

21.9%

416

416/9,039

4.6%

301

301/8,927

3.4%

Bronx

1,918

1,918/9,039

21.2%

1,876

1,876/8,927

21.0%

Manhattan

3,695

3,695/9,039

40.9%

3,471

3,471/8,927

38.9%

Queens

778

778/9,039

8.6%

847

847/8,927

9.5%

Brooklyn

2,180

2,180/9,039

24.1%

2,202

2,202/8,927

24.7%

156

156/9,039

1.7%

171

171/8,927

1.9%

Medicaid

4,668

4,668/9,039

51.6%

4,790

4,790/8,927

53.7%

Medicare

16

16/9,039

0.2%

17

17/8,927

0.2%

Self-payb

923

923/9,039

10.2%

681

681/8,927

7.6%

Other

3,448

3,448/9,039

38.1%

3,439

3,439/8,927

38.5%

Employed total

1,632

1,632/8,988

18.1%

1,627

1,627/8,927

18.2%

Unemployed total

2,766

2,766/8,988

30.6%

2,769

2,769/8,927

31.0%

Disabled

4,590

4,590/8,988

50.8%

4,484

4,484/8,927

50.2%

mean, SD, range

87.3

44.5 (SD)

(0-355)

88.5

34.8 (SD)

(1-355)

>=60 mg

7,249

7,249/9,039

80.2%

7,278

7,278/8,927

81.5%

65+
Borough of residence

Staten Island
Insurance payor

Employment status

Methadone dose
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<60 mg 1,790
1,790/9,039
19.8%
1,649
1,649/8,927
Abbreviations: opioid treatment program (OTP); hepatitis C virus infection (HCV); milligrams (MG); standard deviation (SD)
a

18.5%

Age was calculated at start of the study period: 1/1/2013. The OTP enrolls individuals who are 18 years of age or older.

Most "self-pay" patients are those who have health insurance which included time or visit limited drug treatment benefits which have been
exhausted and who are therefore required to now be self-pay (sliding scale).
b
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Table 2. Hepatitis C virus (HCV) testing and treatment data table for OTP enrolled in 2013-2016
2013-2014 (n= 9,039)

2015-2016 (n= 8,927)

n

n/n

%

n

n/n

%

4,744

4,744/9,039

52.5%

6,545

6,545/8,927

73.3%

1,720

1,720/4,744

36.26%

3,313

3,313/6,545

50.6%

n/a

n/a

n/a

2,987

2,987/3,313

90.2%

n/a

n/a

n/a

1,828/2,987

61.2%

270

270/1,720

15.7%

946/1,828

51.8%

234

234/1,720

13.6%

939/946

99.3%

No. with active virmeia (by at least one
qualitative or one quantitative VL test)

234

234/1,720

13.6%

2,085 c

2,085/3,313

62.9%

No. who received HCV treatment among all
those with documented viremia

28

28/234

12.0%

420

420/2,085

20.1%

No. with at least one HCV antibody test
performed
HCV antibody positive

No. with at least one HCV qualitative viral load
test performed a

HCV qualitative VL reactive

No. with at least one quantitative VL test
performed

HCV quantitative VL detectable
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1,828

946 b

939

b
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No. who received HCV treatment after
successful linkage to HCV care

28

28/234

12.0%

No. who achieved SVR

25

25/28

89.3%

420

420/939

44.7%

414

414/420

98.6%

Abbreviations: opioid treatment program (OTP); hepatitis C virus infection (HCV); viral load (VL); sustained virologic response (SVR)
a

Applies only to those HCV tested in the 2015-2016 time period as qualitative HCV VL testing wasn't introduced into the OTP until 2015

As reflex VL testing was rolled out in a staggered fashion in the first months of 2015, numbers tested for quantitative VL include both 761 who
first had on-site reflex qualitative VL testing as well as 185 who were referred for quantitative VL testing after antibody testing only either in late
2014 or early 2015.
b

While 1,828 individuals had reactive HCV qualitative VL tests, and 939 individuals had reactive HCV quantitative VL tests, 680 individuals were
found to have viremia on both tests (data not shown); hence, (1,828 + 939 ) - 680 = 2,085 individuals with active infection
c
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Table 3. Univariate and Multivariate Associations with Linkage to Care among OTP patients with Active HCV Infection, 2015-2016

Univariatea

Characteristic
Sex

n (N=
1,976)

%

n
Linked
to
Care

pb

%

OR

Multivariatea

pb

95% CI

AOR

95% CI

Male (referent category)

1,476

74.7

628

42.5

.

.

.

.

.

.

.

.

Female

500

25.3

207

41.1

0.65

0.95

0.78

1.2

0.25

0.88

0.71

1.09

18-24 (referent category)

50

2.5

34

1.7

.

.

.

.

.

.

.

.

25-34

255

12.9

170

8.6

0.27

0.71

0.39

1.31

0.35

0.73

0.38

1.42

35-44

378

19.1

256

13.0

0.34

0.75

0.41

1.35

0.52

0.81

0.42

1.54

45-54

602

30.5

473

23.9

0.96

1.01

0.57

1.81

0.97

1.0

0.54

1.90

55-64

603

30.5

450

22.8

0.76

0.91

0.51

1.63

0.63

0.85

0.45

1.61

65+

87

4.4

48

2.4

0.06

0.50

0.24

1.03

0.03

0.4

0.19

0.93

Non-Hispanic White (referent
category)
Hispanic

480

24.3

225

46.7

.

.

.

.

.

.

.

.

923

46.7

354

38.3

0.002

0.71

0.56

0.88

0.002

0.68

0.53

0.87

Non-Hispanic Black

443

22.4

196

44.3

0.42

0.90

0.69

1.17

0.36

0.88

0.66

1.16

Other race/ethnicity

127

6.4

60

47.2

0.94

1.02

0.69

1.50

0.95

1.0

0.7

1.50

824

41.7

399

48.4

.

.

.

.

.

.

.

.

Age (in years)

Race/ethnicity

Borough of Residencec
Manhattan (referent category)

<<91>>

Jordan et al Tables
Bronx

438

22.2

155

35.4

0.001

0.58

0.46

0.74

0.004

0.60

0.47

0.77

Queens

141

7.1

54

38.3

0.03

0.66

0.46

0.95

0.02

0.64

0.44

0.93

Brooklyn

483

24.4

192

39.8

0.002

0.70

0.56

0.88

0.002

0.70

0.55

0.88

Staten Island

34

1.7

13

38.2

0.25

0.66

0.33

1.34

0.24

0.65

0.32

1.33

Other insurance (referent
category)
Medicaid

753

38.1

84

11.2

.

.

.

.

.

.

.

.

1,223

61.2

521

42.6

0.23

0.89

0.73

1.08

.

.

.

.

UHF zip code aread (no referent
category)
Methadone dose

1,976

100.0

835

42.2

0.002

1.02

1.00

1.18

.

.

.

.

Greater than or equal to 60mg
(referent category)
Less than 60mg

1,532

77.5

633

41.3

.

.

.

.

.

.

.

.

444

22.5

202

45.5

0.12

0.84

0.68

1.00

.

.

.

.

Employed (referent category)

298

15.1

119

39.9

.

.

.

.

.

.

.

.

Unemployed

1,672

84.6

712

42.6

0.39

1.12

0.87

1.43

.

.

.

.

Insurance payor

Employment status

Abbreviations: Adjusted odds ratio (AOR); opioid treatment program (OTP); hepatitis C virus
infection (HCV); United Hospital Fund (UHF); milligrams (MG)
a
Logistic regression was used to assess univariate associations; the multi-variate model used logistic regression
Bold font indicates statistical significance
at the <=0.05 level
c
As county of residence and UHF zip code area were highly correlated, only UHF zip
code area was entered in the multi-variate model
d
The 34 UHF zip codes areas were collapsed into 30 zip code areas
due to small cell sizes in 3 UHF zip code areas
b
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Table 4. Hepatitis C virus (HCV) engaged in care community viral load (CVL) among patients in an opioid treatment program (OTP),
New York City
2015-2016: HCV CVL
N

CVL (copies/mL) a

CVL SD b

Female

797

3,965,663

6,242,008

Male

245

3,883,479

6,937,227

Characteristics
Sex

Race/ethnicity

Age (in years)

p-valuec
0.023

0.029
Black, non-Hispanic

270

3,976,651

6,508,311

Hispanic

448

3,733,424

5,794,450

White, non-Hispanic

253

3,978,311

7,141,367

Other race/ethnicity

71

5,060,616

6,963,862

d

0.004
18-24

23

2,138,809

4,003,131

25-34

115

3,068,157

4,800,581

35-44

188

3,893,843

6,076,249

45-54

349

4,278,028

7,681,138

55-64

331

4,116,975

5,925,130

65+

36

3,396,174

3,904,330
0.351

Borough of residence
Bronx

495

3,597,421

5,287,413

Manhattan

190

4,753,923

7,778,317

Queens

71

3,204,971

4,309,483

Brooklyn

246

4,330,097

7,958,986

Staten Island

15

2,008,577

3,728,379

Employment status

0.020
Employed total

140

4,815,964
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7,176,873
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Unemployed total

707

3,725,917

6,276,418

Disabled

191

4,138,561

6,322,261
0.113

Insurance payor
Medicaid

628

4,214,393

7,079,400

Medicare

5

2,065,428

2,672,635

e

Self-pay

85

4,763,063

7,133,472

Other

10

7,402,553

7,608,470
0.428

Methadone dose (mg)
>=60 mg

249

4,047,689

6,462,006

<60 mg

793

3,914,516

6,395,908

(123,945 0.020
20,844,208)
Abbreviations: opioid treatment program (OTP); hepatitis C virus infection (HCV); United Hospital Fund (UHF); milligrams (MG)
UHF zip code area

30

(74 - 77,656,774)

a

Including VLs excluding undetectable VL tests

b

Standard deviations presented reflect standard deviation for the lowest UHF area CVL and for the highest UHF area CVL, respectively

p-value reflects univariate analyses of log-base10 transformed CVL measures examined using linear regression; bold font indicates
statistical significance at the <=0.05 level
c

d

Age was calculated at start of the study period: 1/1/2013. The OTP enrolls individuals who are 18 years of age or older.

Most "self-pay" patients are those who have health insurance which included time or visit limited drug treatment benefits which have been
exhausted and who are therefore required to now be self-pay (sliding scale).
e
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Figure 1. The hepatitis C virus (HCV) care continuum for patients in the opioid treatment program (OTP) 2013-2014 and 2015-2016
9,039
8,927
2013-2014 study period Prior to when
HCV reflex qualitative viral load (VL)
testing was introduced into the OTP in
2015.

2015-2016 study period: After HCV
reflex qualitative viral load testing
was introduced into the OTP in 2015.
73.3%
6,545/8,927
52.5%
4,744/9,039
50.6%
3,313/6,545

90.2%
2,987/3,313
61.2%
1,828/2,987

36.3%

51.8%

1,720/4,744

946/1,828

0%
0 / 4,744
Number in program in
each time period

HCV antibody
tested

HCV antibody
positive

HCV qualitative
VL tested

0%
0 / 4,744

15.7%
270/1,720

Viremic by qualitative
VL testing
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HCV quantitative
VL tested

99.2%
939/946

44.7%
420/939

98.6%
414/420

88.7%
234 / 270

12.0%, 28/234

98.6%, 25/28

Viremic by
quantitative VL

Received HCV
treatment

Sustained virologic
response

Chapter 4. Paper 3: Hepatitis C virus incidence in a cohort in medication assisted treatment for
opioid use disorder in New York City
Abstract

Introduction: Hepatitis C virus (HCV) incidence has increased in the worsening opioid
epidemic. We examined the HCV preventative efficacy of medication assisted treatment (MAT),
and geographic variation in HCV community viral load (CVL) and its association with HCV
incidence.

Methods: HCV incidence was directly measured in an open cohort of patients in a MAT
program in NYC between 1/1/2013–12/31/2016. Area-level HCV CVL was calculated.
Associations of individual-level factors, and of HCV CVL, with HCV incidence were examined in
separate analyses.

Results: Among 8,352 patients, HCV prevalence was 48.7%. Among 2,535 patients
seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation
(PYO). Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female
gender, drug injection, and lower MAT retention were significantly associated with higher
incidence rate ratios. Female gender, drug injection and methadone doses <60mg were
independently associated with shorter time-to-HCV-seroconversion. HCV CVLs varied
significantly by geographic area.

Conclusion: HCV incidence was higher among those with lower MAT retention and was lower
among those receiving higher methadone doses, suggesting the need to ensure high MAT
retention, adequate doses, and increased HCV prevention and treatment engagement. HCV
CVLs vary geographically and merit further study as predictors of HCV incidence.
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Introduction

The current opioid epidemic has led to a rise in HCV incidence by leading to an increase
in drug injection.[1-3] In the US, HCV incident cases rose over 300% from 2010-2015.[1, 3] The
current HCV epidemic is occurring despite the availability of effective HCV primary prevention
and direct acting antivirals agents (DAAs), which can cure HCV infection in over 95% of
cases.[4] All-cause mortality among those with HCV infection and HCV-related mortality both
remain high.[5, 6]
High degrees of coverage of combined prevention with medication assisted treatment
(MAT) (e.g., methadone) for opioid use disorders (OUDs), access to sterile syringes at
needle/syringe programs (NSPs) and pharmacies, and HCV treatment, what could be referred
to as HCV ‘cure as prevention’ (CasP), will be essential for reducing HCV burden among people
who use drugs (PWUD).[7-10]
MAT reduces HCV risk through a reduction in the frequency of drug injection;[11] current
use of MAT reduces HCV acquisition by 40-60%.[10, 12, 13] MAT may be most effective in
preventing HCV when MAT engagement is continuous and when doses are adequate.[13-15]
However, MAT is a complex intervention with significant geographic variation in coverage, and
the evidence-base addressing potentially modifiable factors likely to affect MAT’s HCV
preventive efficacy (e.g., dose, degrees of engagement), is incomplete.[7, 13, 16-19]
Gaps in the implementation of combined evidence-based programs for HCV prevention
persist.[9, 20-22] Over one-third of HCV infected people in New York City (NYC) in 2015-2017
were undiagnosed; and fewer than one-third of those infected received treatment.[23, 24]
Further, critical gaps in MAT availability in relation to need persist; In 2015 in the US <9% of
people received needed MAT.[25-27]
Community viral load (CVL) is a construct that has been applied to HIV
epidemiology.[28-31] HIV CVL is an aggregate measure of HIV viral loads (VL) of individuals in
a program or area and has been shown to be a valuable public health metric; studies have
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identified geographic disparities in HIV CVL with higher mean HIV CVLs in areas with higher
poverty rates, and have found reductions in HIV CVL to be associated with decreased HIV
incidence.[28-31] The magnitude of individual HIV VL increases transmission risk associated
with an exposure event.[32] Studies of HIV CVL have explored a number of CVL measures of
greater or lesser inclusiveness; the former rely on directly measured data, estimation and
imputation, while the latter rely entirely on directly measured data, among those engaged in
care and have been referred to as engaged-in-care CVLs.[33, 34] Analogously, HCV
transmission risk via needlestick is directly correlated with HCV VL magnitude of the source
patient. [35] This suggests that HCV VL magnitude in a PWUD engaged in distributive sharing
will increase transmission risk per event and that the HCV CVL in an area may be an important
driver of HCV incidence and a useful metric of the population-level impact of combined
prevention and CasP.
The availability of DAAs has led to discussions of HCV elimination.[4] The World Health
Organization established a goal of a 90% reduction in new HCV infections by 2030.[36] Yet, the
anticipated beneficial impact of DAAs on HCV incidence derives primarily from modeling, and
direct evidence for their impact on incidence is scarce.[37] In the absence of effective
population-level HCV prevention and CasP, the high prevalence of active, untreated HCV
results in a high CVL, which serves as a large HCV reservoir, increasing the probability of a
non-sterile injection episode with HCV contaminated injection equipment.[8] Thus, accurate
estimates of HCV incidence, optimization of the HCV preventative efficacy of MAT, and
examination of the potential value of public health metrics, such as HCV CVL, are critical to
HCV control.
The objectives of the paper are to calculate HCV prevalence, incidence, and engagedin-care HCV CVL. We examine the impact of methadone dose and of measures of MAT
retention on HCV incidence. Further, we examine geographic variation in HCV CVL and the
impact of area-level HCV CVL on area-level HCV incidence.
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Methods

This study examined an observational retrospective open cohort of patients receiving
MAT for OUDs in an opioid treatment program (OTP) in NYC enrolled at any time between
1/1/2013-12/31/2016.[16, 38] Patient data were collected from electronic medical records and
included HCV antibody, HCV VL tests, and demographic information. Patients were routinely
offered opt-out HCV antibody testing at program entry and annual evaluations, and were tested
unless they declined testing or were known to be antibody positive. This research was approved
by institutional review boards at Mount Sinai Health System and City University of New York.
Definitions

Outcomes of interest
HCV infection was defined as HCV antibody positivity.
Incident HCV infection: Patients were included in HCV incidence calculations if they had
>1 HCV negative antibody tests during the study period followed by >1 HCV antibody tests;
incident HCV was defined as a new positive HCV, after a previous negative HCV antibody, test.
HCV incidence rate: We calculated HCV infection incidence rates (IR), using persontime of observation, presented as rates per 100 person-years of observation (PYO), with 95%
confidence intervals (95% CIs). In incidence analyses, time zero was defined as the date of first
HCV negative antibody test. For those who did not seroconvert, person-time was the time
between the first and last documented negative HCV antibody test. For seroconverters, the date
of incident HCV infection was assigned at the midpoint between the dates of the last observed
negative and the first observed positive HCV antibody test. We also calculated incidence rate
ratios (IRRs) using the Wald unconditional maximum likelihood estimation method (with 95%
CIs).
Exposures of interest
Demographic variables were measured at OTP admission if that occurred during the
study period, or at the first annual evaluation during the study period if they had been admitted
prior to the study period. Methadone dose was calculated as the mean of each patient’s daily
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dose during the study period, then dichotomized at 60 milligrams (mg); this threshold was
chosen based on data that doses > 60mg are most effective in OUD relapse prevention.[39]
The degree of MAT engagement was measured both as 1) a dichotomous variable, MAT
engagement, reflecting whether a patient was continuously enrolled in MAT or was enrolled,
discharged, and readmitted >1 times in the study period, and 2) as a continuous variable, MAT
retention, measuring the total number of days enrolled in MAT during the study period. Patients
were considered as having a main route of drug use by injection if any of their reported primary,
secondary, or tertiary drug of choice were reports to be by injection.
Community viral load (CVL) was calculated using data from patients who had >1 HCV
VL test during the study period 2013-2016 and reflects the mean of the sum of each patient’s
most recent HCV VL test in copies/milliliter (mL) with their standard deviations (SDs). CVLs
were calculated overall and for geographic area of residence using the 34 United Hospital Fund
(UHF) ZIP code aggregations; we then compared the HCV CVLs between different UHF
areas.[40]
Statistical analysis

We assessed differences in first HCV antibody serostatus using the Chi-square test and
examined factors associated with HCV antibody positivity in multivariate logistic regression. We
calculated HCV prevalence, number of HCV seroconversions, IR and IRRs overall and by
individual-level factors, and HCV CVL overall, by individual-level factors, and by area. The
presence of multicollinearity between variables was examined by the variance inflation factor
and in bivariate correlations; multicollinearity was not identified.
Kaplan-Meier plots were drawn to depict the probability of remaining HCV antibody
negative during the study period, overall and by main drug use by injection, gender, MAT
engagement, and methadone dose; we used the Mantel-Cox log-rank test to examine
differences in time-to-seroconversion. We used univariate and multivariate Cox proportional
hazards regression to assess the relationship between time-to-HCV-seroconversion and
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individual-level variables; associations are presented as unadjusted hazard ratios (HR) and
adjusted HRs (aHR) with 95% CIs, respectively.
For all analyses, HCV CVLs were transformed to the log 10 scale; in the tables HCV CVLs
are presented untransformed. Relationships between individual-level factors and HCV CVL
were examined using the Kruskal-Wallis test; differences in HCV CVL by UHF area were
examined using Spearman’s correlation coefficient. We then examined the relationship between
HCV CVL in UHF areas and HCV incidence among UHF areas using a negative binomial
regression where the count of seroconversions was the dependent variable and the natural
logarithm of PYO functioned as an offset term in the model to account for differences in time-atrisk across areas.
Analyses were conducted in R and p-values reported a significance level of 0.05.[41]
Results

There were a total of 8,352 unique patients enrolled in the OTP during the study period
who received >1 HCV antibody test. There were 4,286 patients whose first HCV antibody test
was negative; 2,535 of these patients received >1 subsequent HCV antibody tests; this subset
were assessed for incident HCV. (Figure 1) Patients who did and did not receive antibody
testing did not differ significantly; neither did those receiving precisely two or >2 HCV antibody
tests. (data not shown) Overall HCV prevalence was 48.7% (4,066/8,352; 95% CI: 47.6, 49.7).
HCV prevalence among those reporting, and not reporting, main drug use by injection was
70.5% and 35%, respectively. (Table 1)
In multivariate analyses, HCV antibody prevalence significantly increased with age and
was significantly higher among those whose main drug use was by injection (aOR: 6.68, 95%
CI: 5.97, 7.48). Further, HCV prevalence was significantly lower among non-Hispanic Blacks
than among non-Hispanic Whites (aOR: 0.83, 95% CI: 0.71, 0.98) and was significantly higher
among Hispanics than among non-Hispanic Whites (aOR: 1.23, 95% CI: 1.08-1.41). (Table 2)
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There were 1,009 patients who received quantitative HCV VL testing and contributed to
the HCV CVL measures. (Figure 1)
There were 108 seroconversions during 4,859 PYO; 2.5% (95% CI: 2.1, 3.0) had
seroconverted by the end of the study period. Median person-years contributed were 1.98 years
(25th-75th percentiles: 1.05, 2.37 years). HCV incidence in the overall cohort was 2.25/100 PYO
(95% CI: 1.82,2.68); incidence was 6.70/100 PYO (95% CI: 5.10, 8.78) and 2.89/100 PYO (95%
CI: 2.08, 3.91) among those reporting main drug use by injection and women, respectively.
Lower MAT retention was significantly associated with higher HCV incidence rate ratios (IRR:
1.01, 95% CI: 1.00, 1.02, p-value: 0.03). HCV incidence was significantly higher among those
whose main drug use was by injection (IRR: 5.2, 95% CI: 3.56, 7.58) and for females (IRR:
1.49, 95% CI: 1.02, 2.20). Incidence was slightly higher among those whose methadone doses
were <60mg compared to those with doses > 60 mg (IRR: 1.44, 95% CI: .97, 2.13). IRs and
IRRs did not differ significantly by race/ethnicity. (Table 2)
Figure 2 presents the Kaplan-Meier curves and Mantel-Cox log rank tests for time-toHCV-seroconversion by gender, methadone dose and MAT engagement, and main drug use by
drug injection. After 4 years of follow-up, >20% of patients reporting main drug use by injection
had acquired HCV infection compared to <2% of those not reporting main drug use by injection
(HR:5.11, 95% CI:3.50, 7.46). (Figure 2a, Table 3)
In our multivariate Cox proportional hazards model controlling for individual-level
characteristics, female sex (aHR: 1.52, 95% CI: 1.03, 2.23), main drug use by injection (aHR:
5.98, 95% CI: 3.98, 8.98) and doses <60mg (aHR: 1.52, 95% CI: 1.03, 2.24) all were
independently associated with shorter time-to-HCV seroconversion. Lower MAT retention was
slightly associated with a longer time-to-HCV-seroconversion (aHR: 1.01, 95% CI: 1.00, 1.02).
(Table 3)
The overall mean HCV CVL was 3,583,742.9 copies/mL (SD: 6,133,314). Mean HCV
CVL increased with patient age (p-value: 0.005). Non-Hispanic Blacks had a higher mean CVL
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than non-Hispanic Whites and than all others, but not significantly so and with a very large
standard deviation. UHF level HCV incidence rates ranged from 0.00/100 PYO (95% CI: 0.000.03) to 9.89/100 PYO (95% CI: 1.20-35.73). (data not shown) HCV CVLs varied significantly by
UHF area (Spearman’s R: -0.44, p-value: 0.008). (Table 4)
In negative binomial regression analysis examining the relationship between area-level
HCV CVL and area-level HCV incidence rates, the HCV IRR associated with a 1 log 10 increase
in HCV CVL was 2.72 (95% CI: 0.77 – 11.13, p-value: 0.147).
Discussion

We identified an HCV incidence rate of 6.7/100 PYOs among those in MAT whose main
drug use was by injection. This rate is lower than incidence rates often observed in out-oftreatment, or recent, people who use drugs.[10, 13, 14, 22] In our study, female sex was
associated both with higher HCV incidence rates and shorter time-to-HCV-seroconversion
corroborating other emerging data;[42, 43] in a recent study which controlled for individual risk
behaviors, females were found to have a higher HCV incidence, higher IRR, and a shorter-timeHCV-seroconversion suggesting that some combination of biologic, social and structural factors
may contribute to an increased risk among females.[42, 44] We found that non-Hispanic Blacks
had a lower HCV prevalence and Hispanics had a higher HCV prevalence than non-Hispanic
Whites but that incidence and IRRs did not differ significantly by race/ethnicity. These
observations merit further study and likely merit focused interventions to address race/ethnicity
disparities in HCV prevalence and gender disparities in HCV incidence.
Our data demonstrate that PWUD who do not report that injection is among their main
routes of drug use have HCV incidence rates higher than the general population. The HCV
incidence observed was many fold higher than the 1 per 100,000 population HCV incidence
observed in the US in 2016.[45] Further, HCV prevalence among those not reporting main drug
use by injection was 35%, more than 10 fold higher than the 3.25% prevalence observed in the
baby boomer birth cohort.[46] The 1.3/100 PYO incidence of HCV we observed among those
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whose main drug use was not by injection may reflect either that these patients did inject nonsterilely (without themselves considering injection one of their main routes of drug use), or may
reflect other modes of transmission such as use of contaminated non-injection drug use
equipment or sex with blood present.[38] This highlights the importance of MAT to reduce HCV
incidence among those with OUDs, both among those who do inject (to reduce injection
frequency) and who do not inject (to prevent transitions to injection) and the importance of HCV
testing among PWUD regardless of reported route of use.
Our work contributes to the limited literature examining the impact of continuous MAT
engagement during follow-up for HCV incidence.[10] While measures reflecting duration of
lifetime injection may be most relevant for HCV prevalence and measures reflecting recent
injection (e.g., ever in the past 6 months) may best reflect current HCV injection risk, individuals
transition between periods of injection and non-injection use. In fact, “reverse transitions” from
injection to non-injection drug use have been adopted by some PWUD as a means of harm
reduction and such reverse transitions have been associated with decreases in HCV
incidence.[47]
The HCV incidence rates identified in our study reflect incidence among patients
enrolled in MAT and receiving repeated HCV testing; HCV incidence may have been higher in
the absence of MAT. Nonetheless, our approach of examining incidence based on the first
negative HCV test while enrolled in MAT allows an examination of the potential impact of
specific MAT factors: methadone dose, and MAT engagement and retention. Our finding that
methadone doses of <60 mg were significantly associated with a shorter time-to-HCVseroconversion adds to the existing but modest literature identifying this association.[15, 39, 48]
This highlights the importance not only of expanding MAT access but also in ensuring high
quality MAT through provision of adequate doses.
Studies examining HCV incidence as a function of degree of MAT retention as a
continuous variable are scarce. A recent Cochrane review identified that most studies of the
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impact of MAT on HCV incidence examined a variable of ‘current’ MAT use; some used a
definition of ‘ever’ having been in MAT.[10] We found that the more days a patient was not
retained in MAT, the higher the risk for HCV seroconversion, and that more days not retained in
MAT was slightly associated with shorter time-to-HCV-seroconversion; these data add support
to the growing evidence base suggesting that efforts to improve not only access to MAT but also
greater MAT retention (i.e., increasing the days that an individual is retained in MAT) will be
important to HCV control.[7, 12, 14, 48]
While these data are derived from patients receiving MAT for OUDs, they were mostly
not in HCV care. One of the major factors contributing to the lesser population-level impact of
combined prevention on HCV control (compared to HIV control) is that while that HIV treatment
was made available at public health scale, the same has not yet been fully accomplished for
HCV treatment.[37, 49]
Our study contributes to the literature by applying the CVL construct to HCV
epidemiology and by examining area-level variations in HCV CVL and its association with arealevel HCV incidence.[28, 31] We found that HCV CVL varied significantly among UHF areas.
Geographic variation in HCV CVL has also been recently reported in Houston, Texas.[19] These
data suggest that measures of HCV CVL may be valuable in geographically focusing both harm
reduction and CasP efforts to achieve HCV control. Our study also found that for each 1 log 10
increase in HCV CVL, the HCV incidence rate was expected to be multiplied by about 2.7,
although this association was not statistically significant. Our data are consistent with the
general inference that the CVL in an area may contribute to incidence by increasing the risk
associated with any single non-sterile injection event. As acute HCV infection and HCV
incidence are difficult to identify and measure directly, if HCV CVL were found to be a valid
predictor of incidence it would be a valuable metric for HCV control efforts. Further, since
individuals remain HCV antibody after treatment and cure, metrics reflecting active HCV
infection, such as CVL, may assume increasing importance as CasP is increasingly
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implemented. Our findings, and these considerations, suggest the importance of further
research using datasets examining a greater number of geographic areas, more person-time, as
well as possible refinements in how HCV CVL is measured, including more inclusive HCV CVL
measures, in order assess the potential value of the HCV CVL concept more precisely.[34]
Limitations
This study has limitations that must be noted. Analyses were of PWUD in MAT in OTP
who may differ from those not in OTP thereby limiting generalizability. Analyses were conducted
among those who received HCV antibody testing; while it is plausible that those tested may
have differed from those untested, we did not identify differences between these groups.
Our incidence analyses examining the impact of MAT did not adjust for access to sterile
syringes through NSPs or pharmacies as individual-level data on patients’ sterile syringe use
were unavailable; however, the OTP studied was in NYC, an area of high sterile syringe access.
Our CVL analyses were limited by the modest number of geographic areas, of incident
infections, by modest person-time, and by use of a CVL measure relying exclusively on directly
measured data and which therefore may not fully reflect OTP patients who were not fully tested
or other PWUD who may be linked to OTP patients through risk networks; more inclusive CVL
measures which utilize both directly measured data and estimation and imputation merit further
study.[34] A more refined measure of CVL could also reflect the aggregate of both individual
VLs and individual degree of distributive risk behavior.
Strengths of this work included the use of longitudinal data to directly calculate
incidence, assessment of the impact of methadone dose and MAT retention on the HCV
preventative efficacy of MAT, examination of sex disparities in HCV incidence, assessment of
incidence among those whose main drug use was not by injection, and the examination of
geographic variation in HCV CVL and the impact of area-level HCV CVL on area-level HCV
incidence.
Conclusion
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The worsening HCV epidemic causes significant morbidity and mortality despite the
availability of known primary prevention and highly efficacious HCV treatment which can result
in cure. The incidence rates observed in our study support recommendations for annual HCV
testing of all those in MAT, not only of those who report injecting drugs.[50] Interventions (at
individual-, provider-, program-, and policy-levels) to ensure adequate methadone dosing and
enhanced MAT engagement and retention and, when relevant, to link MAT patients to sources
of sterile syringes for primary HCV prevention, may be valuable strategies to enhance HCV
control. .[7, 8, 10, 12, 17, 18] The finding that HCV IRRs and time-to-seroconversion were
shorter among females suggests that further studies of, and efforts to address, these disparities
are needed. HCV CVLs vary geographically suggesting a need to geographically focus
prevention and treatment efforts. Further study of potential racial/ethnic and gender disparities
in HCV prevalence and HCV CVL are warranted. HCV CVLs merit further study as predictors of
HCV incidence and as metrics of HCV prevention and treatment efforts.
The large reservoir of chronically infected persons and current HCV incidence rates
reinforce the need for vigorous efforts to expand MAT access and ensure appropriate doses,
continuous engagement, and improved retention, and to the need to expand and geographically
focus HCV prevention and treatment to achieve HCV CasP and HCV control.
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Table 1. Characteristics of patients in an opioid treatment program in NYC, 2013-2016 and associations with HCV seroprevalence
HCV
HCV
Overall study population HCV
antibody
antibody
antibody tested
negative
positive
HCV
prevalence
N*
%
N
N

Multivariate logistic regression model of HCV serostatus
Univariate pvalue3

Adjusted
odds ratio

Lower limit
95% CI

Upper limit
95% CI

p-value

Individual-level characteristics1,2
8,352
100.0%
4,286
4,066
48.7%
n/a
n/a
n/a
n/a
n/a
Age, in years
<0.001
18-24 years
350
4.2%
257
93
26.6%
ref
.
.
.
25-34 years
1,293
15.5%
808
485
37.5%
2.11
1.59
2.81
<0.001
35-44 years
1,708
20.5%
959
749
43.9%
3.62
2.72
4.81
<0.001
45-54 years
2,852
34.1%
1,593
1,259
44.1%
5.10
3.84
6.78
<0.001
55-64 years
1,851
22.2%
587
1,264
68.3%
14.39
10.69
19.36
<0.001
65+ years
291
3.5%
77
214
73.5%
16.90
11.35
25.17
<0.001
Race/ethnicity
<0.001
non-Hispanic White
2,290
27.4%
1,191
1,099
48.0%
ref
.
.
.
Hispanic
3,739
44.8%
1,836
1,903
50.9%
1.23
1.08
1.41
0.002
non-Hispanic Black
1,825
21.9%
1,009
816
44.7%
0.83
0.71
0.98
0.025
Other
498
6.0%
250
248
49.8%
0.93
0.73
1.17
0.521
Gender
0.28
Male
6,073
72.7%
3,083
2,985
49.2%
ref
.
.
.
Female
2,277
27.3%
1,201
1,076
47.3%
1.05
0.93
1.17
0.45
Employment
<0.001
Employed
1,532
18.3%
932
600
39.2%
ref
.
.
.
Unemployed
6,820
81.7%
3,354
3,466
50.8%
1.52
1.31
1.76
<0.001
Veteran Status
<0.001
Not a veteran
7,897
94.6%
4,095
3,802
48.1%
ref
.
.
.
Veteran
455
5.4%
191
264
58.0%
1.23
0.98
1.54
0.07
Insurance Payor
<0.001
Medicaid
4,938
59.1%
2,429
2,509
50.8%
ref
.
.
.
Other
1,012
12.1%
541
471
46.5%
1.16
1.03
1.30
0.02
Self-pay
2,402
28.8%
1,316
1,086
45.2%
0.80
0.67
0.96
0.02
Education
<0.001
Higher education beyond HS
2,018
24.2%
1,166
852
42.2%
ref
.
.
.
Less than HS
3,097
37.1%
1,536
1,561
50.4%
1.39
1.22
1.58
<0.001
HS diploma or GED
3,129
37.5%
1,576
1,553
49.6%
1.37
1.20
1.58
<0.001
Reported main drug use by injection
<0.001
No
5,131
61.4%
3,337
1,794
35.0%
ref
.
.
.
Yes
3,221
38.6%
949
2,272
70.5%
6.68
5.97
7.48
<0.001
Methadone dose (in milligrams)
0.464
>= 60 mg
5,065
60.6%
2,625
2,440
48.2%
n/a
n/a
n/a
n/a
< 60 mg
3,236
38.7%
1,632
1,604
49.6%
n/a
n/a
n/a
n/a
MAT engagement 4
<0.001
Continuous engagement in MAT
4,531
54.3%
2,208
2,323
51.3%
n/a
n/a
n/a
n/a
Interrupted engagement in MAT
3,821
45.7%
2,078
1,743
45.6%
n/a
n/a
n/a
n/a
MAT retention 4
Days active in the OTP (mean, SD)
1,189
909.33
.
.
.
.
n/a
n/a
n/a
n/a
Days not active in the OTP (mean, SD)
30
129.78
.
.
.
.
n/a
n/a
n/a
n/a
Repeat HCV Ab test after first HCV Ab neg 4
Only one HCV Ab test (row percentages)
4,289
51.4%
1,751
2,560
59.7%
.
n/a
n/a
n/a
n/a
More than one HCV Ab test
4,063
48.6%2
.
.
.
.
n/a
n/a
n/a
n/a
Abbreviations: New York City (NYC); Hepatitis C virus (HCV); antibody (Ab); high school (HS); graduate equivalent degree (GED); medication assisted treatment (MAT); methadone maintainence treatment (MMT); antibody (Ab); opioid
treatment program (OTP); milligrams (mg); standard deviation (SD)
1

The numbers in the columns labeled N reflect those with data available. Missing data were <3%; no multicollinearity identified.

2

N and % are presented for each individual-level characteristic unless otherwise specified

3

Chi-square test for categorical variables and Wilcoxon test for continuous variables; comparison was between those HCV antibody positive and HCV antibody negative; values in bold were statistically significant based on a priori pvalue determination of p <0.05
4

These individual-level characteristics were not included in the multivariate logistic regression model of HCV serostatus as they include data from the time period after the baseline assessment of serostatus.
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Table 2. HCV incidence and HCV incidence rate ratios among an open cohort of patients receiving medication assisted treatment for opioid use disorder in NYC

Incidence rate ratio

Incidence rate
Individual-level characteristics1
Overall
Age, in years
18-24 years
25-34 years
35-44 years
45-54 years
55-64 years
65+ years
Race/ethnicity
non-Hispanic White
Hispanic
non-Hispanic Black
Other
Gender
Male
Female
Employment
Employed
Unemployed
Veteran Status
Not a veteran
Veteran
Insurance Payor
Medicaid
Other
Self-pay
Education
Less than HS
HS diploma or GED
Higher education beyond HS
Reported main drug use by injection
No
Yes
Methadone dose (in milligrams)
>= 60 mg
< 60 mg
MAT engagement
Continuous engagement in MAT
Interrupted engagement in MAT
MAT retention, in days (mean, SD)

Total N

Incident HCV N

PYO

per 100 PYO

95% CI LL

95% CI UL

IRR

95%
CI LL

95%
CI UL

p-value2

.

.

.

.

2,535

108

4859

2.25

1.82

2.68

85
387
537
1,056
417
48

5
19
18
36
27
3

121
668
991
2149
837
84

4.12
2.80
1.80
1.67
3.22
3.55

1.33
1.71
1.08
1.17
2.13
0.73

9.62
4.44
2.87
2.31
4.69
10.40

1.00
0.68
0.44
0.41
0.78
0.86

.
0.26
0.16
0.16
0.30
0.20

.
1.84
1.18
1.03
2.03
3.61

.
0.45
0.13
0.08
0.59
0.87

622
1,148
587
178

30
52
18
8

1100
2244
1160
354

2.72
2.31
1.55
2.25

1.84
1.73
0.92
0.97

3.89
3.04
2.45
4.45

1.00
0.85
0.57
0.83

.
0.54
0.32
0.38

.
1.33
1.02
1.81

.
0.48
0.60
0.66

1,782
751

66
42

3405
1450

1.94
2.89

1.50
2.08

2.47
3.91

1.00
1.49

.
1.02

.
2.20

.
0.04

606
1,924

23
85

1202
3657

1.91
2.32

1.21
1.86

2.87
2.87

1.00
1.21

.
0.77

.
1.92

.
0.41

2,412
123

102
6

4622
237

2.20
2.53

1.79
0.93

2.67
5.50

1.00
1.15

.
0.50

.
2.60

.
0.71

1,869
427
240

79
19
11

3676
399
784

2.14
4.75
1.40

1.70
2.86
0.70

2.67
7.42
2.50

1.00
2.22
0.65

.
1.34
0.34

.
3.65
1.22

.
<0.001
0.18

949
939
639

46
37
23

1869
1770
1209

2.46
2.10
1.90

1.80
1.47
1.20

3.28
2.88
2.85

1.00
0.84
0.78

.
0.55
0.47

.
1.31
1.28

.
0.46
0.33

52
492

52
56

4025
834

1.30
6.70

0.96
5.10

1.70
8.70

1.00
5.20

.
3.56

.
7.58

.
<0.001

1,738
780

68
40

3429
1400

1.98
2.86

1.54
2.00

2.50
3.90

1.00
1.44

0.97

2.13

0.07

1,725
810

78
30

3654
1205

2.13
2.50

1.68
1.68

2.66
3.55

1.00
1.17

.
0.77

.
1.78

.
0.46

40.8 (139.8)

70.0 (198.0)

n/a

n/a

n/a

n/a

1.01

1.00

1.02

0.03

Abbreviations: New York City (NYC); hepatitis C virus (HCV); person-years of observation(PYO); antibody (Ab); high school (HS); graduate equivalent degree (GED); medication assisted treatment (MAT); methadone maintenance
treatment (MMT); antibody (Ab); opioid treatment program (OTP); milligrams (mg); standard deviation (SD); confidence interval (CI); lower limit (LL); upper limit (UL); person-years of observation (PYO); incidence rate ratio (IRR)
1

The numbers in the columns labeled N reflect those with data available. Missing data were <3%; no multicollinearity identified.

2

p-value; statistical significance of rate difference; values in bold were statistically significant based on a p-value of <0.05.
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Table 3. Time to HCV seroconversion by characteristics of 2,535 HCV antibody-seronegative patients enrolled in an opioid treatment program in NYC, 2013-2016

Adjust
ed
Hazard
Ratio3
1.03

Hazard
95% CI
p95%
95%
pIndividual-level characteristics1
N2
%_2
Ratio
95% CI LL
UL
value
CI LL
CI UL
value4
Age, in years (mean and SD)
45.33
10.70
1.03
0.98
1.02
0.73
1.01
1.05
<0.001
Age, in years
2535
18-24 years
85
3%
ref
.
.
.
25-34 years
387
15%
0.54
0.28
1.97
0.74
35-44 years
537
21%
0.14
0.18
1.28
0.48
45-54 years
1056
42%
0.09
0.18
1.15
0.45
55-64 years
417
16%
0.76
0.33
2.25
0.86
65+ years
53
2%
0.76
0.19
3.35
0.80
Race/ethnicity
non-Hispanic White
1148
45%
ref
.
.
.
ref.
.
.
.
Hispanic
587
23%
0.66
0.39
1.13
0.13
0.73
0.42
1.26
0.26
non-Hispanic Black
622
25%
1.15
0.73
1.80
0.54
0.82
0.50
1.33
0.41
Other
178
7%
0.96
0.46
2.02
0.92
0.83
0.39
1.75
0.62
Gender
Male
1784
70%
ref
.
.
.
ref.
.
.
.
Female
751
30%
1.49
1.01
2.19
0.04
1.52
1.03
2.23
0.03
Employment
Unemployed
606
24%
ref
.
.
.
Employed
1929
76%
0.83
0.52
1.31
0.43
Veteran Status
Not a veteran
2412
95%
ref
.
.
.
Veteran
123
5%
1.15
0.50
2.61
0.75
Insurance Payor
Medicaid
1868
74%
ref
.
.
.
Other
427
17%
1.03
0.63
1.71
0.90
Self-pay
240
9%
1.54
0.82
2.90
0.18
Education
Higher education beyond HS
639
25%
ref
.
.
.
HS diploma or GED
939
37%
1.10
0.66
1.86
0.71
Less than HS
957
38%
1.36
0.83
2.24
0.22
Reported main drug use by injection
No
2043
81%
ref
.
.
.
ref.
.
.
.
Yes
492
19%
5.11
3.50
7.46
0.00
5.98
3.98
8.98
<0.001
Methadone dose, mg (mean, SD)
81.71
41
1.03
0.99
1.00
0.21
Methadone dose, mg
>= 60 mg
1755
69%
ref
.
.
.
ref.
.
.
.
< 60 mg
780
31%
1.41
0.95
2.08
0.08
1.52
1.03
2.24
0.03
MAT engagement
Continuous engagement in MAT
1725
68%
ref
.
Interrupted engagement in MAT
810
32%
1.04
0.68
1.59
0.85
MAT retention, days inactive or not retained (mean, SD)
40.87
140
1.10
1.11
1.12
0.02
1.01
1.00
1.02
0.07
Abbreviations: New York City (NYC); hepatitis C virus (HCV); antibody (Ab); high school (HS); graduate equivalent degree (GED); medication assisted treatment (MAT); methadone maintenance treatment (MMT); antibody
(Ab); opioid treatment program (OTP); milligrams (mg); standard deviation (SD); confidence interval (CI); lower limit (LL); upper limit (UL); person-years of observation (PYO)
1

The numbers in the column labeled N reflect those with data available. Missing data were <3%; no multicollinearity identified

2

N and % are presented for each individual-level characteristic except as otherwise specified for the variables age, methadone
dose, and MAT retention
3

Multivariate model included age (as a continuous variable), gender, race/ethnicity, reported main drug use by injection, methadone dose (dichotomous), MAT engagement (continuous)

4

The values in bold were statistically significant based on a p-value of <0.05
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Table 4. Hepatitis C virus (HCV) community viral load (CVL)and univariate associations for patients in an opioid treatment program in NYC, 2013-2016
Individual-level characteristics1

N

%

Mean CVL

CVL SD

p-value2

Overall
1,009
100%
3,583,742.9
6,133,314
n/a
Age, in years
0.005
18-24 years
22
2.2%
2,057,538
3,651,791
25-34 years
98
9.7%
2,822,991
4,057,202
35-44 years
175
17.3%
3,162,512
4,550,681
45-54 years
341
33.8%
3,809,692
6,341,650
55-64 years
333
33.0%
3,969,522
5,450,024
65+ years
38
3.8%
2,932,791
3,530,230
Race/ethnicity
0.09
non-Hispanic White
252
25.0%
3,549,630
5,253,802
Hispanic
435
43.1%
3,174,546
4,351,025
non-Hispanic Black
254
25.2%
4,085,511
7,082,772
Other
66
6.5%
4,463,736
5,679,993
Gender
0.50
Male
765
75.8%
3,551,500
5,397,555
Female
242
24.0%
3,681,253
5,462,181
Employment
0.17
Employed
133
13.2%
4,714,177
6,391,286
Unemployed
874
86.6%
2,717,093
2,320,797
Veteran Status
0.48
Veteran
64
6.3%
3,477,293
7,831,622
Not a Veteran
943
93.5%
5,135,516
5,205,816
Insurance Payor
0.13
Medicaid
666
66.0%
3,687,084
5,630,153
Other
102
10.1%
10,035,246
7,386,687
Self-pay
239
23.7%
2,764,247
3,617,036
Education
0.79
Less than HS
395
39.1%
3,517,255
4,710,260
HS diploma or GED
395
39.1%
3,492,736
5,614,784
Higher education beyond HS
204
20.2%
3,815,818
5,990,518
Unknown
13
1.3%
4,645,185
8,423,787
Reported main drug use by injection
0.16
Yes
544
53.9%
3,441,366
5,055,684
No
463
45.9%
3,748,720
5,820,709
Methadone dose (in milligrams)
0.57
>= 60 mg
603
59.8%
3,666,703
5,433,123
< 60 mg
398
39.4%
3,468,724
5,407,571
MAT engagement
0.16
Continuous engagement in MAT
649
64.3%
3,866,577
5,963,782
Interrupted engagement in MAT
358
35.5%
3,068,023
4,301,752
Abbreviations: New York City (NYC); hepatitis C virus (HCV); antibody (Ab); high school (HS); graduate equivalent degree (GED); medication assisted treatment (MAT); methadone maintenance treatment (MMT); antibody (Ab);
opioid treatment program (OTP); milligrams (mg); standard deviation (SD)
1
The numbers in the column labeled N reflect those with data available. Missing data were <3%; no multicollinearity identified
2
p-value by Kruskal-Wallis test and HCV CVL to the logbase10 was used in analyses, values in bold were statistically significant based on a p-value <0.05
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Figure 1. Consort diagram of study population and hepatitis C virus (HCV) measures of interest
10,864 unique patients
enrolled in the OTP
2,512 did not have any documented HCV
antibody testing
8,352 patients with an
HCV antibody test

4,066 patients HCV
antibody positive

4,286 patients HCV
antibody negative

2,535 patients received
more than one HCV
antibody test

108 patients had incident
HCV infection

3,082 patients did not
quantitative viral load
testing

1,009 patients received
quantitative HCV viral load
testing
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First HCV antibody test
contributing to HCV
prevalence measure

Repeat HCV antibody
testing contributing to
HCV incidence calculation

2,427 patients remained
HCV antibody negative

HCV quantitative viral load
testing contributing to HCV
community viral load measure
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Chapter 5. Summary of findings, further areas of research, conclusion
This dissertation contributes to the literature by addressing several gaps in the evidence base
regarding HCV epidemiology and HCV control.
This dissertation makes a novel and substantive contribution to the literature by applying the CVL
construct to HCV epidemiology. Through a systematic review in Paper 1, I demonstrate that there were
no published studies applying the CVL construct to HCV epidemiology, neither theoretically nor
qualitatively; only one abstract examining HCV CVLs has been presented subsequently.[162] Paper 1
further contributes to the scientific literature by adapting the CVL construct, which had originally been
developed and utilized for understanding HIV epidemiology, to apply to HCV epidemiology. I present a set
of measures of HCV CVL that can be utilized to answer different questions related to HCV control and I
demonstrate that these HCV CVLs can be practically measured or calculated; the HCV CVL measures
proposed can be constructed by either only incorporating directly measured HCV VLs, or by using both
directly measured HCV VLs and imputed VLs to attempt to more fully account for those undiagnosed or
those not in care.
This dissertation then operationalizes one of the HCV CVL constructs in Papers 2 and 3, and
makes a novel contribution to the literature by calculating HCV CVL using empiric data, by examining its
variation based on geographic units (i.e. UHF zip code areas in NYC) and by demographic subgroups,
and by examining the relationship between HCV CVL and area-level incidence. HCV CVLs were found to
vary significantly geographically suggesting that HCV CVL measures may be useful in geographically
focusing HCV services. In negative binomial regression analysis examining the relationship between
area-level HCV CVL and area-level HCV incidence rates, the HCV IRR associated with a 1 log 10 increase
in HCV CVL was 2.7; while not significant, this finding suggests the important of further research on this
association. The studies’ findings are consistent with the inference that the CVL in an area may contribute
to incidence by impacting the risk of transmission through any non-sterile injection event.
My data and findings, and future use of HCV CVL measures, could be useful to health
departments to monitor area-level trends in HCV epidemiology as part of ongoing surveillance, to inform
geographically focused combined HCV prevention efforts (primary prevention), and to focus efforts to
increase engagement in HCV treatment and HCV CasP (secondary prevention). These CVL measures
could also be used in quantitative evaluations of the effectiveness of the implementation of specific
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interventions (e.g., impact of HCV prevention programs, HCV testing initiatives, scale-up of HCV
treatment availability) on HCV incidence and prevalence. Identifying variations in HCV CVL could be
useful to HCV control by contributing to assessments of area-level risk of HCV outbreaks and potentially
as a surrogate measure of the potential for injection-related HIV outbreaks.
Prior work had established that few studies have examined multiple sequential HCV care
continuum outcomes from the initial step of antibody testing through confirmatory testing, linkage-to-care,
and HCV treatment outcomes.1 This dissertation contributes to the literature by doing so. In Paper 2, I
have shown that rates of HCV testing, linkage-to-care, and HCV treatment among those in the OTP all
increased significantly during the study period. While the net number and proportion of people engaged in
HCV care increased, engaged-in-care HCV CVLs did not decrease over the time period studied; this is
likely due to the fact that despite the significant increase in linkage-to-care, which was notable in
magnitude, there remained a very high unmet treatment need. Therefore, despite the fact that OTP
patients who engaged in HCV treatment did complete HCV treatment and had a roughly 95% cure rate,
there were too few patients treated to have a significant impact on engaged in care HCV CVL and total
CVL. These findings are consistent with the inference that current combined HCV control strategies have
not included a sufficient expansion of HCV treatment. These data strongly suggest that further
improvements in testing and linkage-to-treatment are needed to address the large unmet treatment need
in order to control the HCV epidemic among PWUD.
Further, Paper 2 demonstrated that large gaps with respect to testing remained. I have shown
that despite a system of routine opt-out HCV testing, many patients were not tested and many initially
found to be HCV negative were not re-tested to identify incident infection despite ongoing HCV risk. The
different testing strategies analyzed in the two time periods examined are the two testing strategies
commonly employed in OTPs and HCV testing sites nationally.1-3 I found that the HCV reflex testing can
be implemented at scale to facilitate the detection of active HCV infection. My findings clearly point to the
utility of reflex qualitative HCV VL testing in facilitating the identification of active viremia in a single
testing step; this is an important public health strategy that should be expanded to more OTPs and other
HCV testing sites.
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Efforts to expand HCV testing and to address gaps in the care continuum are needed both at
MAT program entry, at which time many PWUD opt-out of testing, and longitudinally, where there are
missed opportunities for follow-up testing to identify incident infection. For those enrolled in MAT, efforts
to expand baseline and annual follow-up testing are needed. Furthermore, because periods of time in
which patients become unengaged from MAT are periods of increased risk, retesting at program re-entry
(such as after incarceration and release) is an important opportunity to identify incident infection as well.
In the cohort I studied, there was a significant increase in the proportion linked to HCV care in
2015-2016 compared to 2013-2014. While HCV care continuum outcomes were significantly improved in
the time period when reflex qualitative VL testing was employed and DAAs were available, large numbers
of patients remained untested, undiagnosed or incompletely evaluated, and unmet treatment need and
engaged-in-care CVLs remained high (as discussed above). Among those found to have active HCV
infection by reflex testing in 2015-2016, Hispanics were less likely than non-Hispanic Whites to be
successfully linked-to-care. Whether this was due to issues of language or other aspects of ethnicitybased marginalization is not clear; nonetheless, more potent linkage-to-care efforts are needed broadly,
and especially for those of Hispanic ethnicity.
Furthermore, in comparing the two time periods examined there was a significant, albeit small,
increase in HCV treatment rates among those linked to care. While reasons for this are not certain, it is
possible that the use of reflex testing and the fuller identification of active infection may have increased
individual motivation to engage in HCV treatment and/or may have increased program efforts to link
actively infected patients to care. It is likely that both the wider availability of oral DAA therapy and wider
understanding that HCV treatment can be effective among PWUD contributed to these increases. 4-6
Nonetheless, strategies to increase engagement in treatment are needed; these may include
interventions to increase patient acceptance and provider willingness to treat, and to reduce insurance
and other structural barriers to treatment.7,8
Paper 3 contributes to the literature by directly measuring HCV incidence among PWUD in MAT
in a longitudinal study design, including examination of the potential role of CVL. The overall HCV
incidence rate was 2.3/100 PYOs. I identified an incidence rate of 6.7/100 PYOs among those whose
main drug use was by injection. These data are consistent with prior data demonstrating that HCV
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incidence is high among PWID.9-11 This incidence rate among PWID in MAT is lower than that generally
reported among PWID not in MAT, and while not derived from data with a direct comparison group, it is
nonetheless consistent with other data demonstrating that MAT engagement is associated with lower
HCV incidence.9-12
These data contribute to the limited literature on HCV incidence among PWUD who do not inject;
data presented in Paper 3 show that PWUD who do not report that injection is their main route of drug
use also have HCV incidence rates higher than the general population. The HCV incidence observed was
many fold higher than the 1 per 100,000 population HCV annual incidence observed in the US in 2016. 13
The 1.3/100 PYO incidence of HCV observed among those whose main drug use was not by injection
may reflect either that these patients did in fact inject non-sterilely while themselves not considering
injection one of their main routes of drug use, or acquisition may reflect other modes of transmission such
as use of contaminated non-injection drug use equipment or even during sex with blood present. 14,15 The
relevant HCV incidence among those not reporting injection drug use highlights the importance of MAT to
reduce HCV incidence among those with OUDs, both among those who do inject (to reduce injection
frequency) and who do not inject (to prevent transitions to injection), and the importance of HCV testing
among PWUD regardless of reported route of drug use.
While measures reflecting duration of lifetime drug injection may be most relevant for assessing
HCV prevalence and measures reflecting recent injection (e.g., ever in the past 6 months) may best
reflect incidence risk related to injection risk, it is important to recognize that individuals transition
between periods of injection and non-injection use. In fact, “reverse transitions” from injection to noninjection drug use have been adopted by some PWUD as a means of harm reduction and such reverse
transitions have been associated with decreases in HCV incidence.16 This study of PWUD receiving MAT
for OUDs reflects a population whose frequency and route of drug use varies over time. The HCV
incidence rates identified in Paper 3 demonstrate that despite MAT’s beneficial HCV preventive efficacy,
there is ongoing transmission while being enrolled in MAT. Nevertheless, HCV incidence may have been
higher for these PWUD in the absence of MAT. By demonstrating that patients in MAT remained at risk of
HCV, these data support the conclusion that there is a need for interventions to link patients in MAT to
sources of sterile syringes for primary HCV and HIV prevention.12,17-22
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Paper 3 addresses an important gap in the literature by examining the impact of MAT
engagement as a continuous variable on the HCV preventative efficacy of MAT. A recent Cochrane
review identified that most studies of the impact of MAT on HCV incidence examined a dichotomous
variable of ‘current’ MAT use reflecting either use in the past 1-to-6 months or merely use at the time of
an interview; some used a definition of ‘ever’ having been in MAT.12 Paper 3 makes an important
contribution by demonstrating that higher degrees of MAT engagement, measured as a continuous
variable of days engaged in MAT during the study period, was protective against HCV after adjustment
for a range of individual-level characteristics. My work therefore contributes to the scarce literature
examining the impact of continuous MAT engagement on HCV incidence. 23 My finding that fewer days
retained in MAT was significantly associated with higher incidence rate ratios, and that fewer days of MAT
retention was slightly associated with shorter time-to-HCV-seroconversion, add support to the growing
evidence base suggesting that efforts to improve not only access to MAT but greater continuous
engagement will be important in HCV control efforts.18,20,24-27
Some published research suggests that females, despite having a higher rate of spontaneous
clearance of HCV infection, are at higher risk of acquiring HCV infection than males. 9,28-37These findings,
along with the findings from Paper 3, suggest that interventions that address and reduce this genderbased disparity in HCV incidence are needed.
There are large gaps in the public health-level implementation of MAT for OUDs and in the
delivery of HCV treatment and CasP to people with HCV. This dissertation contributes to the literature by
demonstrating substantial gaps in the scale-up of HCV treatment even among those in MAT. While these
data are from patients receiving MAT for OUDs, these patients were mostly not in HCV care. One of the
major factors contributing to the lesser population-level impact of combined prevention on HCV control
(compared to HIV control) is that while that HIV treatment has been made available at public health scale,
the same scale has not yet been fully accomplished for HCV treatment.38-40 This reaffirms prior
observations that there is a tremendous need to expand HCV treatment within MAT programs and/or to
expand linkage to HCV treatment from MAT programs.6
Limitations of this work
This work has limitations that must be noted. Several key limitations will be noted here and
specific limitations are more fully discussed in the Discussion sections of each paper. The studies in
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Papers 2 and 3 were retrospective analyses of routinely collected clinical data. Key disadvantages of
relying on retrospective data include that data were not complete for all examined variables (e.g., HCV
status), and detailed individual risk behavior data were not available. This limited the ability to fully
consider some relevant factors such as frequency of injection, frequency of receptive or distributive
syringe sharing, and use of SSPs.
With respect to assessments of incidence, one specific limitation is that not all patients were HCV
tested; however, the completeness of HCV testing among patients enrolled in MAT was in fact part of the
study question and findings (Paper 2). The issue of data completeness in studies of HCV incidence
frequently impacts the findings in the published literature, particularly the literature examining the impact
of MAT on HCV incidence. In addition, by studying only those enrolled in MAT, CVL measures do not
incorporate data from other PWUD who may be linked to MAT participants through risk networks.
Furthermore, examined associations could be confounded by other unmeasured factors. Despite these
limitations, the data (Paper 3) contribute substantively to the literature by providing longitudinal
measurements of HCV incidence and data on the impact on incidence of specific MAT factors including
methadone dose and both dichotomous and continuous measures of retention.
Further research and program/policy implications
1. While rates of HCV testing, linkage-to-care, and HCV treatment all increased significantly from 20132014 to 2015-2016, engaged-in-care HCV CVLs did not decrease over time, likely due to the low
numbers of those treated. Further research on promising interventions to increase HCV testing, retesting, linkage to HCV-care, and to ensure treatment initiation and completion, as well as, the impact
of HCV CVL on CasP, are needed. Such studies need to address intervention efficacy, barriers and
facilitators at the structural and individual levels, and the population-level effectiveness of
interventions at scales sufficient to move towards HCV elimination.
2. There are disparities between males and females regarding HCV incidence and time to HCV
seroconversion; females had both a higher HCV incidence rate and had shorter times to HCV
seroconversion. In a recent study which controlled for individual risk behaviors, females were found to
have higher HCV incidence rates, suggesting that some combination of biologic, social and structural
factors may contribute to an increased risk in females.9,41 Further research is required to better
understand these findings in order to be able to adequately address them. In addition, further
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research is needed on disparities between males and females with OUD engaged in MAT regarding
HCV risk and both MAT engagement and HCV care continuum outcomes.
3. More work is needed to study HCV incidence among PWUD who do not identify as people who inject
drugs (whether due to issues of lack of self-identification or to lack of willingness to disclose) to
delineate the extent to which incident HCV in this population is due to unreported injection, to other
routes of drug use, to other modes of parental transmission such as tattooing or to sexual
transmission.
4. The finding that HCV CVL varied geographically may be related to geographic variations in HCV
testing and treatment and/or in geographic variations in access to MAT and/or other factors; this
requires further study. However, in NYC, where both HCV services and MAT are frequently available
and accessible, research should explore in ecologic analysis the potential impact of other area-level
factors on this geographic disparity in HCV CVL. Further, whether there are analogous spatial
relationships between policing activities and access to MAT, and whether policing activities diminish
the HCV preventive efficacy of MAT should be explored.42-47
5. In negative binomial regression analysis examining the relationship between area-level HCV CVL and
area-level HCV incidence rates, the finding that the HCV IRR associated with a 1 log10 increase in
HCV CVL was 2.72 (95% CI: 0.77 – 11.13, p-value: 0.147), although not statistically significant,
suggests the importance of further research on this association. (Paper 3) This future research would
benefit from examining a greater number of geographic areas, more person-time, as well as possible
use of additional CVL measures, including those requiring imputation (to assess whether the added
methodologic complexity also adds predictive value) and would benefit from examining this
association in a range of settings of high and low HCV prevalence and incidence.
6. Further analyses of geographic variation in HCV CVL and associations between HCV CVL and
incidence should include analysis of both the impact of social network factors and of area-level
variation in structural factors such as rates of poverty and economic inequality, of criminal justice and
policing factors, as well as access to HCV and MAT services.
7. That this dissertation measured MAT as a continuous, rather than dichotomous, exposure is a
strength since continuous measures provide more information than dichotomous measures. Use of a
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continuous measure addresses a current gap in the scientific evidence base which predominately has
only studied MAT engagement as either a lifetime exposure or as a dichotomous exposure. Future
research should continue to examine the role of MAT as a continuous exposure on HCV prevention.
8.

While this dissertation demonstrated that more days of MAT retention and doses >60mg are
associated with lower HCV incidence, further research is needed solidify the understanding of how
these and other aspects of MAT such as clinic hours and take-home dose options contribute to HCV
prevention.

Concluding remark
This body of research demonstrates that HCV CVL can be used to identify area-level disparities
in HCV burden and control and that further studies of the relationship between HCV CVL and area-level
incidence are needed. These data suggest that measures of HCV CVL may be valuable in geographically
focusing prevention and treatment efforts so as to most effectively reduce the burden of HCV morbidity
and mortality now, and in the coming decades.
Analyses identified significant losses in the HCV care continuum steps of testing, linkage-to-care,
and treatment. Further improvements in rates of complete testing are needed and broader
implementation of HCV reflex testing may be valuable. More potent linkage-to-care interventions are
needed generally and particularly for those of Hispanic ethnicity. While during the study period the
proportion HCV treated increased significantly, there were still very high rates of unmet treatment need
suggesting that HCV control will require significant expansion of HCV treatment.
The incidence rates observed support recommendations for annual HCV testing of all those in
MAT, not only those who report injecting drugs. Data highlight the need for efforts to improve MAT
retention and ensure adequate dosing. Further studies of and efforts to address identified sex disparities
are needed. Area-level HCV CVL measures may be valuable to geographically focus prevention and
treatment efforts and merit further study as predictors of incidence.
PWUD engaged in MAT continue to be at risk for HCV infection. The large reservoir of PWUD
chronically infected with HCV, and persistently high HCV incidence rates, reinforce the need for vigorous
efforts to improve HCV care continuum outcomes and ensure access to high-quality MAT. Efforts to
expand HCV treatment access and engagement are essential to promote HCV CasP and achieve HCV
control.
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Appendices
Appendices to Chapter 2
Appendix A: PROSPERO form for conducting the systematic review
Systematic Review: Applications of the community viral load (CVL) construct to hepatitis C virus (HCV)
epidemiology.
Objective: Characterize the published data on application of CVL constructs to HCV epidemiology.
Time frame: 1/1/1991 – 12/31/2017
Electronic databases to be searched: PubMed, Embase, non-PubMed MEDLINE articles, and the
Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials
(CENTRAL).
Types of studies to be included: Any reports which discuss the application of the CVL construct to HCV
epidemiology and identify primary research reports presenting HCV CVL using an observational study
design (e.g., case-control, cohort, ecologic) in which quantitative HCV RNA viral load data are aggregated
to produce group-, area-, or program-level measures.
Domain being studied: Active HCV infection measured by quantitative HCV RNA tests (which provide
data on the amount of virus in the blood), aggregated to produce group-, area-, or program-level
measures.
Population under study: There will be no restrictions to the populations in the included reports due to the
anticipated scarcity of studies addressing the research question.
Exposure(s): Active HCV infection measured by quantitative HCV RNA testing.
Outcome(s): HCV CVL measures.
Data selection and coding: Abstracts of potentially eligible reports will be reviewed and full-text reports will
be assessed for inclusion among those reports whose abstracts were assessed to provide potentially
useful data. The net number of reports assessed at each step will be tracked and presented in a PRISMA
flow diagram; the reasons for exclusion of reports at the full-text assessment step will be documents.
The study will first make an assessment of the number of reports discussing the application of the CVL
construct to HCV epidemiology, regardless of whether quantitively determinations are actually made.
These publications will be described qualitatively. However, only those providing primary data of
quantitative HCV viral load data aggregated at the group-, area-, or program-level will be eligible for
inclusion in the formal systematic review.
After full-text review of potentially eligible reports, the eligible reports will undergo data extraction; the
following fields will be extracted from each eligible report:
1.
2.
3.
4.

Publication details: author(s), funding source(s), year, journal, title;
Population characteristics;
Group-, area-, or program-level characteristics;
Study characteristics: research question, HCV testing specifics and testing sample details (type of
test, time, frequency), study design details, sample side, study time period, etc.;
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5. Outcome(s): quantitative HCV viral load aggregated at the group-, area-, or program-levels and
any reported relationships to other outcomes (e.g., incidence), time-to-event data when relevant,
follow-up time for the study, type of individual or population-level outcome(s) considered; and
6. Study conclusion;
Strategy for data synthesis: A systematic review will be conducted but given the scarcity of eligible reports
that are anticipated, it is not likely data will allow a meta-analysis.
We anticipate that there may be articles aggregating VLs among patient populations and that these
aggregations may be most often presented as either mean or median VLs. For these reports, we
anticipate that the grouped VLs will not be used as a population-level or area-level predictor or
explanatory factor but rather be used descriptively to characterize a patient population (e.g., HCV positive
people receiving care at an HIV clinic) or to predict responses to a specific health intervention (e.g., HCV
treatment).
A summary table will enumerate and describe any reports discussing the application of the CVL construct
to HCV epidemiology. A PRISMA flow diagram delineating reports providing any discussion of the CVL
construct applied to HCV epidemiology and any reports providing quantitative group-, area-, or programlevel measures will be constructed. The narrative synthesis will include description of the range of eligible
reports as well as an exploration of any patterns in the data extracted from the eligible reports. Similarities
and differences among the eligible reports will be explored systematically and possible explanations for
similarities and differences will be considered in a logical way. Where data allow, a forest plot of eligible
reports and summary table will be constructed.
If possible, reports will be grouped based on the type of outcome(s) they use HCV CVL to either predict
or explain.
As part of the overall conceptual analysis of HCV viral load and population health, the eligible reports will
be assessed for how the results of the research studies might be affected by factors including
methodological differences across studies or differences in characteristics of the population.
A conceptual model may be developed to explore the relationships and patterns in the included reports; a
simple schematic may be useful to contextualize the results of the included reports.
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Appendix B: Search strategy
(1)

PubMed = 316 Search Results

(((((Hepacivirus/classification[MeSH Terms]) OR (Hepatitis C/epidemiology[MeSH Terms]) AND
("Hepatitis C"[MeSH Terms]) OR ("Hepatitis C, Chronic"[MeSH Terms]) OR (Hepatitis C/virology[MeSH
Terms]) OR (Hepatitis C Antibodies/blood[MeSH Terms]) OR (Hepatitis C Antibodies) OR (Hepatitis C
Virus)) AND ("Community viral load" OR "aggregate viral load" OR "median viral load" OR "mean viral
load" OR "mode viral load" OR "HCV elimination")))) AND (((RNA, Viral/blood[MeSH Terms]) OR (Viral
load[MeSH Terms]) OR (RNA, Viral)))
(2)

Medline, Embase = 262 search results

1. ("community viral load" or "aggregate viral load" or "median viral load" or "mean viral load" or “HCV
elimination” or “hepatitis c virus elimination”).af.
2. ("HCV" or "hepatitis C virus").af.
3. ("Viral load" or "RNA").af.
(3)

Cochrane CENTRAL = 6 search results

ID
Search
#1
"hepatitis C virus":ti,ab,kw in Trials (Word variations have been searched)
#2
("community viral load" or "aggregate viral load" or "median viral load" or "mean viral load" or
“HCV elimination” or “hepatitis c virus elimination”)
#3
#1 and #2
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